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Abstract 
Infectious disease is a significant cause of morbidity and mortality in cats and dogs.  The 
diagnosis of the causative agent is essential to allow for the appropriate clinical 
intervention, to reduce infection spread, and also to support epidemiological studies which 
in turn will better the understanding of infectious disease transmission and control.  The 
polymerase chain reaction (PCR) has replaced traditional detection methods as the gold 
standard diagnostic technique for many pathogens, however replacing traditional detection 
methods with panels of internally controlled multiplex real-time PCR screens designed 
along syndromic lines is not widespread.  The aim of this thesis is to undertake the 
development phase of a wider project that intends to develop a broad panel of syndrome 
based real-time PCR multiplex assays for infectious diseases in cats and dogs. 
 
In order to achieve this, appropriate extraction and real-time PCR platforms and reagents 
were chosen.  The aim of this project was to begin the development of five syndrome 
based panels of multiplex screens:- feline respiratory disease, feline conjunctivitis, feline 
anaemia, feline gingivitis, and feline and canine gastroenteritis.  The multiplex assays were 
optimised and then evaluated through a series of experiments to determine the endpoint 
sensitivity, specificity and robustness of each multiplex in comparison to the single assays.  
The full optimisation and pre-clinical validation assessment of five multiplex assays was 
completed in the timescale of this project; the feline respiratory screen, the feline 
conjunctivitis screen and the feline/canine gastroenteritis 1, 2 and 3 screens. 
 
This study highlighted some of the difficulties that can be encountered when developing 
in-house multiplex real-time PCR assays.  The main limitations were the lack of readily 
available positive control material, published assays and sequence data.  The results of this 
study highlight that the development of an in-house multiplex real-time PCR diagnostic 
service can be at times difficult and occasionally time-consuming.  A significant finding of 
this study was that PCR may not be as sensitive as virus isolation in the detection of feline 
calicivirus (FCV).  It is hoped that further work including additional sequencing will aid in 
the development of a more sensitive FCV PCR assay.  In-house multiplex real-time PCR 
should bring many advantages over current veterinary diagnostic assays.  This will in turn 
aid in the treatment and clinical management of the animal, and increase our understanding 
of infectious disease in cats and dogs.  
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CHAPTER 1 
1. Introduction  
1.1 Importance of feline and canine infectious disease  
Infectious disease is a significant cause of morbidity and mortality in cats and dogs.  
Viruses are the major cause of disease although bacteria, parasites and fungi are commonly 
implicated.  To combat these infectious agents, anti-bacterial, anti-viral and anti-parasitic 
medicines and vaccines have been developed and marketed for companion animal use.  
Figures published by the National Office of Animal Health (NOAH) who represent 
companies that research, develop, manufacture and market animal medicines in the UK, 
show that £554 million was spent over the 12 month period between September 2012 and 
2013 on animal medicines, 53.5% of which has been spent on companion animals such as 
cats and dogs (NOAH, 2014).  This is a rise of 32% since 2005 (£374 million).  When 
established in 1986, NOAH reported that the majority of animal medicine costs (70%) 
were for livestock animals, therefore the data above highlights a significant shift in the 
market.  These figures can be partially attributed to the fact that 77% of UK companion 
animal owners regard their pet’s health as important as, or more important than, their own, 
with 16% claiming to visit their vet more than their own doctor (NOAH, 2014). 
 
Despite the willingness of owners to invest in their pets’ health, infectious agents remain a 
significant cause of disease.  Vaccines are not available for all known pathogens; in any 
event, no vaccine is 100% protective, and vaccine breakthrough infections can occur 
(Chalmers, 2006).  Many human anti-viral agents are not suitable for veterinary use, 
whereas only feline recombinant interferon omega (rfeIFN-), Virbagen Omega (Virbac, 
Bury St. Edmunds, UK), is licensed for use in veterinary species.  The movement towards 
multi-animal and/or indoor households and the rise in shelter accommodation readily 
facilitates the transmission of many infectious agents.  Some infections can rapidly become 
enzootic within these multi-animal environments, such as feline enteric coronavirus 
infection. 
 
Rapid, sensitive and specific detection of the causative agent is vital to allow for the 
appropriate clinical intervention (Greiner and Gardener, 2000; Zarlenga and Higgins, 2001; 
Dahlhausen, 2010; Belak et al, 2013).  It is also important for infection control, and for 
epidemiological studies, to improve our understanding of infectious disease transmission 
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and prevalence in cats and dogs.  Detection of veterinary infectious agents has traditionally 
relied upon techniques such as virus isolation, bacterial culture, serological assays, electron 
microscopy and others.  These traditional techniques can be hugely labour intensive and 
time consuming.  These detection methods can also be insensitive and occasionally non-
specific.  The polymerase chain reaction (PCR) is now being used more widely in 
veterinary diagnostics, especially with the advent of real-time PCR which provides rapid 
results, from receiving the sample into the laboratory a result can be obtained in as little as 
two to three hours.  Since PCR assays can be designed to detect DNA or RNA (RT-PCR), 
viruses, bacteria, parasites or fungi, multiple pathogens can be targeted from a single 
sample.  A further benefit to real-time PCR is the ability to multiplex more than one single 
PCR assay together to allow for the simultaneous detection of multiple pathogens in one 
reaction well. 
 
1.2 Important feline and canine infectious diseases 
1.2.1 Feline respiratory disease 
Respiratory disease in cats is common and presents particular management problems in 
multi-cat environments such as shelters, breeding colonies and boarding catteries.  The 
most significant pathogens are feline herpesvirus (FHV) and feline calicivirus (FCV); 
however the bacterium Bordetella bronchiseptica (B. bronchiseptica) is also considered a 
primary respiratory pathogen (Table 1.1).  Feline herpesvirus and FCV infections can 
result in severe disease, which can be fatal in young, immunocompromised or 
unvaccinated animals.  The prevalence of all three pathogens generally increases 
proportionally to the number of cats housed in a group.  The prevalence of FHV is around 
20%, with increased risk in cat shelters (reviewed by Thiry et al, 2009).  The prevalence of 
FCV has been found to range between 25% and 40%, with prevalence within individual 
colonies ranging from 50 to 90% (reviewed by Radford et al, 2009).  For B.bronchiseptica, 
as with FHV and FCV, prevalence is variable between studies and the size of group of cats, 
prevalence has been found to be between 0.4% and 19% in cats (reviewed by Egberink et 
al, 2009). 
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Table 1.1 Important veterinary pathogens  
Syndrome 
 
Pathogen Vaccine 
available?* 
Traditional Gold 
standard 
Cat Dog 
Respiratory Feline herpesvirus Core n/a Virus isolation 
Feline calicivirus Core n/a Virus isolation 
Bordetella bronchiseptica Non-
core 
Non-
core 
Culture 
Conjunctivitis Feline herpesvirus Core n/a Virus isolation 
Mycoplasma felis n/av n/a Culture 
Chlamydophila felis Non-
core 
n/a Culture 
Gastroenteritis Parvovirus Core Core Electron microscopy 
on faeces 
Salmonella n/av n/av Culture 
Campylobacter n/av n/av Culture 
Coronavirus n/l Non-
core 
None  
Cryptosporidium parvum n/av n/av Ziehl-Neelsen smear 
Giardia lamblia n/av n/av Zinc sulphate 
floatation 
Tritrichomonas foetus n/av n/av Microscopy 
Anaemia and 
Gingivitis 
Feline leukaemia virus Non-
core 
n/a Virus isolation 
Feline immunodeficiency 
virus 
n/l n/a Virus isolation 
Feline infectious 
peritonitis (FCoV) 
n/l n/a None, 
histopathology 
Feline calicivirus  Core n/a Virus isolation 
Haemoplasmas n/av n/a Microscopy 
* only applicable to the UK.  n/a: not applicable; n/l: not licenced; n/av: not available; FCoV: feline coronavirus 
This table summarises important veterinary pathogens of cats and dogs, the syndromes that they cause, the vaccines available, and the 
traditional gold standard method for diagnosis.  
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1.2.1.1 Feline herpesvirus  
Feline herpesvirus is an alpha-herpesvirus containing double stranded (ds) DNA with a 
glycoprotein-lipid envelope and little strain variation, antigenically all FHV strains belong 
to one serotype (Maggs, 2005; Thiry et al, 2009).  Feline herpesvirus causes “cat-flu”, 
often accompanied by systemic signs of disease such as fever, depression and anorexia.  
Following recovery, the virus remains latent within the nerve ganglia of the head and is 
periodically shed at times of stress.  During reactivation, few particles are shed and for a 
very short time.  Frequently, reactivating infection is associated with single presentations 
such as conjunctivitis, corneal ulceration, rhinitis or sinusitis.  The gold standard detection 
method for FHV has been virus isolation; however this has widely been replaced with PCR 
(Burgesser et al, 1999).  Treatment for cats is mainly supportive; however antiviral 
treatments such as famciclovir have been shown to be effective in resolving clinical signs 
(Malik et al, 2009; Thomasy et al, 2011).  A vaccine for FHV is available (Table 1.1) and 
recommended (Thiry et al, 2009; Day, Horzinek and Schultz, 2011); this vaccine is given 
as a trivalent vaccine with FCV and feline parvovirus (FPV). 
 
1.2.1.2 Feline calicivirus 
Feline calicivirus is a small, non-enveloped, single stranded (ss) RNA virus, and a member 
of the vesivirus genus of the Calicivirus family.  Infection with FCV causes a range of 
clinical signs due to differences of tropism and virulence in different strains (Gaskell, 
Dawson and Radford, 2011).  Some strains are non-pathogenic whereas others are more 
virulent.  Many vaccinated cats can become infected due to variation of strains as the 
vaccine strains do not cross-protect against all strains or the virulent strains (Radford et al, 
2007).  FCV has a well characterised carrier state (Radford, 1998) and asymptomatic cats 
can shed virus.  In addition, vaccinated cats can become infected with field strains without 
showing clinical signs.  Feline calicivirus infection results in less severe respiratory disease 
than FHV infection.  In recent years there have been an increasing number of reports of 
highly virulent FCV haemorrhagic strains causing systemic infections with high mortality 
(Meyer et al, 2011), these strains can cause virulent-systemic disease (VSD) and can infect 
vaccinated cats.  There has been no consistent molecular difference between haemorrhagic 
strains and other strains found, and there is no consistent genetic motif that differentiates 
between haemorrhagic and non-haemorrhagic strains, therefore VSD cannot be identified 
by molecular typing methods (Hurley et al, 2003).  However these strains are genetically 
different from vaccine and non-haemorrhagic strains and differ from outbreak to outbreak 
suggesting that these strains evolve independently (Coyne et al, 2006; Porter et al, 2008).  
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The gold standard for FCV detection is virus isolation.  Treatment for FCV-related 
respiratory disease could include antivirals (i.e. rfeIFN-), however no large properly 
controlled trials have not been carried out to demonstrate their efficacy.  Prophylaxis is 
available as a trivalent vaccine with FHV and FPV (Table 1.1) and is recommended 
(Radford et al, 2010; Day, Horzinek and Schultz, 2011). 
 
1.2.1.3 Bordetella bronchiseptica 
Bordetella bronchiseptica is a bacterial pathogen of cats and dogs that can cause a wide 
range of respiratory signs including mild illness, fever and coughing, to severe pneumonia 
and death, especially in the young and immunocompromised.  Bordetella bronchiseptica is 
an aerobic Gram-negative coccobacillus.  The gold standard detection method is bacterial 
culture.  Animals with severe B. bronchiseptica infection require antimicrobial therapy, 
supportive therapy and intensive nursing care.  It should be noted that B.bronchiseptica can 
be an opportunistic pathogen in humans therefore infection in animals may have public 
health implications.  Treatment with antibacterial therapy is indicated to prevent infection 
progressing to colonise the lower respiratory tract (Egberink et al, 2009).  A vaccine is 
available (Table 1.1) but is generally recommended only if a cat is to be boarded in a 
cattery (Day, Horzinek, and Schultz, 2011). 
 
1.2.2 Feline conjunctivitis 
Feline herpesvirus together with Chlamydophila felis (C. felis) are the most common 
causes of conjunctivitis in cats; infection is particularly severe in young kittens, 
Mycoplasma felis (M. felis) is associated with feline conjunctivitis; however the 
importance of M. felis as a primary agent is not yet fully understood.  Feline herpesvirus 
has already been discussed in Section 1.2.1.1. 
 
1.2.2.1 Chlamydophila felis 
Chlamydophila felis (formally Chlamydia psittaci) is a Gram-negative rod-shaped 
bacterium.  It causes unilateral to bilateral ocular disease, with an initial watery discharge.  
Transmission is by close contact with infected cats, and ocular secretions are the most 
likely route of transmission as the bacterium is unable to survive outside the host (Sykes 
and Greene, 2011).  A study by Di Franceso, Piva and Baldelli (2004) found that C .felis 
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was detected by PCR in 12 to 20% of cats with conjunctivitis, with detection low in 
healthy cats at two to three percent.  The traditional detection method for C. felis was 
bacterial culture using McCoy’s cells (Wills, Johnson and Thompson, 1984) but PCR is 
now the preferred method for diagnosis since culture was difficult and relatively 
insensitive.  Treatment with antibiotics is recommended, and systemic treatment is more 
effective than topical treatment (Dean et al, 2005).  A vaccine is available (Table 1.1) and 
recommended only in at-risk cats (Day, Horzinek and Schultz, 2011).  
 
1.2.2.2 Mycoplasma felis 
Mycoplasma spp. are prokaryotes, the smallest free-living microorganisms.  Mycoplasma 
felis is suspected to be a significant pathogen in conjunctivitis of cats (Greene and Chalker, 
2011), however little data is available on the prevalence of M. felis.  The gold standard 
method traditionally used to detect M.felis is bacterial culture, although molecular 
techniques are now available (Chalker et al, 2004).  Mycoplasma felis can be treated with 
systemic antibiotics, and no vaccine is available (Table 1.1) (Day, Horzinek, and Schultz, 
2011). 
 
1.2.3 Feline anaemia 
Several infectious causes of anaemia in cats have been identified and characterised, such as 
feline leukaemia virus (FeLV), feline immunodeficiency virus (FIV), feline coronavirus 
(FCoV) and the haemoplasmas (Table 1.1). 
 
1.2.3.1 Feline leukaemia virus 
Feline leukaemia virus (FeLV) is a retrovirus that infects cats worldwide.  The virus is an 
enveloped single stranded (ss) RNA gamma retrovirus that infects domestic cats and other 
exotic felidae.  Over the past 25 years, the prevalence and importance of FeLV infection in 
Europe has greatly decreased - thanks to reliable tests, ‘test-and-removal’ programmes of 
viraemic carriers, an improved understanding of FeLV pathogenesis and the introduction 
of effective vaccines (Lutz et al, 2009).  
 
Transmission occurs mainly through friendly contacts, such as mutual grooming, but also 
through bites.  Infection results in several outcomes: - (1) abortive infection; (2) regressive 
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infection; (3) progressive infection; and (4) focal or atypical infection (Hartmann, 2011).  
Feline leukaemia virus can cause varying clinical signs as the clinical course of disease is 
determined by a combination of host and viral factors.  Most persistently infected cats die 
within three and a half years of infection, usually as a result of immunosuppression.  Feline 
leukaemia virus is also aetiologically associated with tumours, haematological disorders 
and immune-mediated disease (Hartmann, 2011).  Many types of anaemia can be caused 
by FeLV, approximately 10% are regenerative, however the majority are non-regenerative 
and caused by the virus suppressing the bone marrow (Hartmann, 2011).  Infection with 
FeLV-C infection is a very rare cause of aplastic anaemia, arising due to mutation of the 
envelope gene in individual animals (Onions et al, 1982).  Cats infected with feline 
leukaemia virus can be diagnosed by detection of FeLV p27 antigen using ELISA, proviral 
DNA using PCR, or whole infectious virus by virus isolation (Hartmann, 2011).  Different 
therapies, including antivirals are available for cats with FeLV.  The therapy is largely 
dependent on the disease caused by the virus, however it should be noted that no properly 
controlled trials of antivirals have been carried out.  Many vaccines are marketed for FeLV 
however these are not considered core vaccines (Table 1.1), and none are 100% effective 
(Day, Horzinek and Schultz, 2011). 
 
1.2.3.2 Feline immunodeficiency virus  
Feline immunodeficiency virus (FIV) is a retrovirus of the genus lentivirus that is closely 
related to human immunodeficiency virus (HIV), sharing a similar structure, life cycle and 
pathogenesis (Sellon and Hartmann, 2011).  Infected cats generally remain free of clinical 
signs for several years, and some cats never develop disease.  Typical manifestations are 
chronic gingivostomatitis, chronic rhinitis, lymphadenopathy, weight loss and immune-
mediated glomerulonephritis.  Additional clinical signs are the consequence of the cat 
being immunosuppressed and more susceptible to secondary infection.   
Since FIV was discovered in 1986, serological studies have demonstrated that the virus is 
enzootic in domestic cat populations worldwide; the seroprevalence of FIV is highly 
variable between regions, with estimates of one to 14% in cats with no clinical signs and 
up to 44% in sick cats (Sellon and Hartmann, 2011).  The major route of natural 
transmission is via biting.  The clinical stages of disease are not fully defined, with 
different research groups having different findings.  The recognised phases are like HIV; 
an acute phase, an asymptomatic phase and a terminal phase (AIDS).  Other studies have 
found up to six stages (Sellon and Hartmann, 2011).  Overall the clinical signs of FIV 
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infection are non-specific.  Like FeLV, FIV suppresses the bone marrow which can result 
in the cat becoming anaemic.  As with FeLV, therapies are available for FIV including 
antiviral chemotherapy and immunomodulatory therapy.  The most common diagnostic 
assay for FIV is antibody testing.  Virus isolation is time consuming, and technically 
challenging with limited commercial availability.  A vaccine is available for FIV (Table 
1.1), but is not licensed in the UK due to questionable efficacy (Day, Horzinek, and 
Schultz, 2011). 
 
1.2.3.3 Feline Coronavirus 
Feline coronavirus can be divided into two biotypes: feline enteric coronavirus (FECV) 
and feline infectious peritonitis virus (FIPV).  Approximately one to three percent of 
FECV-seropositive cats develop lethal FIPV, with stress predisposing to the development 
of disease (Addie, 2011).   More than one theory exists on how FIPV develops; one is that 
it is a result of mutations of FECV during intestinal replication, the ‘in vivo mutation’ 
theory.  An alternative hypothesis is the ‘circulating virulent/avirulent’ theory, where both 
virulent and avirulent strains circulate in the cat population and susceptible cats exposed to 
the virulent strains develop FIPV (Pedersen, 2009).  Non-effusive FIPV is the more 
chronic form of the disease and is associated with a non-regenerative anaemia (Addie, 
2011).  FIP is a fatal condition, with a median survival of nine days after diagnosis (Truyen 
et al, 2009).  Some studies have been carried out to detect messenger (m)RNA in the blood 
(Simons et al, 2005; reviewed by Pedersen, 2009).  However a subsequent study found that 
mRNA testing may not be specific (Can-Sahna et al, 2007), therefore the reliability of this 
method is still unclear and studies are ongoing.  Vaccination is available in the USA and 
some European countries, but not in the UK (Table 1.1) (Day, Horzinek, and Schultz, 
2011). Vaccination is ineffective in seropositive cats. 
 
1.2.3.4 Feline haemoplasmas 
Three haemoplasmas are known to infect cats: Mycoplasma haemofelis (Mhf), 
“Candidatus Mycoplasma haemomintum” (CMt), and “Candidatus Mycoplasma 
turicensis” (CMhm).  Similarity between the three organisms is only approximately 83% 
(Messick and Harvey, 2011). 
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The haemoplasmas are cell wall-free bacteria that attach to red blood cells.  Infections in 
domestic cats can induce acute haemolysis, and the disease is characterized by anorexia, 
lethargy, dehydration, weight loss, and sudden death (Willi et al, 2007).  The immune 
system of the cat may also cause the death of red blood cells as it tries to kill the parasite 
attached.  Anaemia is generally regenerative and can be severe.  The prevalence of CMt 
was found to be 0.5% to 10% in sick cats, and CMhm which is thought to have low 
pathogenic potential (Peters et al, 2008) has a similar prevalence rate.  Mycoplasma 
haemofelis is the least prevalent, found in 0.5% to 6% of sick cats (Sykes, 2010).  The 
haemoplasmas cannot be cultured in artificial media and the low numbers of organisms 
present result in blood smear examination being an insensitive diagnostic test.  PCR is used 
to detect the bacteria in blood when too few organisms are present to make a diagnosis 
using blood smears (Messick and Harvey, 2011).  The haemoplasmas can be treated with 
doxycycline (Sykes, 2010). 
 
1.2.4 Feline Gingivostomatitis 
Despite its common occurrence, the aetiology of chronic gingivostomatitis in cats remains 
uncertain.  Feline calicivirus, FeLV and FIV are all thought to be associated with 
gingivostomatitis in cats (Healey et al, 2007) (Table 1.1), however direct causation has not 
been proven (Greene and Marks, 2011).  Studies have found varying prevalence of FCV, 
FeLV, and FIV in affected cats (reviewed in Healey et al, 2007).  Gingivostomatitis is the 
most common syndrome in FIV infected cats, and FCV concurrent infection is often 
detected (Hartmann, 2012).  However, a recent study by Belgard et al (2010) suggests that 
in fact FCV is the only significant cause of gingivostomatitis in cats.  Nonetheless, the 
cause of gingivostomatitis in cats is controversial, highlighting the need for a rapid 
screening assay that can simultaneously detect FCV, FIV and FeLV in symptomatic cats, 
to study the prevalence of these viruses and so better the understanding the infectious 
causes of gingivostomatitis in cats.  The recommended vaccination for these viruses is 
described above and in Table 1.1. 
 
1.2.5 Feline and canine gastroenteritis 
Many pathogens, including viral, bacterial, and parasitic organisms, can cause 
gastroenteritis in cats and dogs, with mixed infections being common (Paris et al, 2014).  
Given the large overlap in clinical signs, it is difficult to distinguish pathogens clinically.  
It is therefore important to correctly identify the causative pathogen(s) in order to use the 
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correct treatment and apply appropriate infection control measures.  The key pathogens 
that cause feline and canine gastroenteritis are canine and feline parvovirus (CPV and 
FPV), Salmonella serovars, Campylobacter jejuni (C.jejuni), feline and canine enteric 
coronaviruses (FCoV and CCoV), Cryptosporidium parvum (C.parvum), Giardia lamblia 
and Tritrichomonas foetus (T.foetus).  In addition, enterotoxigenic strains of Clostridium 
perfringens (C.perfringens), Clostridium difficile (C.difficile) and Escherichia coli (E.coli) 
can also cause gastroenteritis in dogs, and occasionally cats (Table 1.1). 
 
1.2.5.1 Parvovirus 
Canine and feline parvovirus (CPV and FPV) are small non-enveloped DNA viruses that 
require rapidly dividing cells for replication.  The viruses are extremely stable and resistant 
in the environment for up to one year (Greene, 2011
a
).  Transmission of the virus occurs as 
a result of contact with infected faeces in the environment.  The viruses primarily attack 
the gastrointestinal tract leading to sloughing of intestinal epithelium; the virus also 
reduces white blood cell numbers therefore compromising the immune system.  Feline 
parvovirus is also known as feline panleucopenia virus; clinical signs can include high 
fever, depression, lack of appetite, diarrhoea and vomiting.  Peracute infection causes 
sudden death, usually in kittens but occasionally in adults.  A study by Paris et al (2014) 
found 22.1% of diarrheic cats to have FPV by real-time PCR.  Transmission is usually 
indirect as FPV persists in the environment for up to one year.  Transplacental transmission 
leads to cerebellar hypoplasia in kittens. 
 
CPV-1 was discovered in 1967, and a new variant CPV-2 was discovered in 1978.  By 
1979 another more aggressive variant CPV-2a was discovered, and over the last 30 years, 
CPV-2b (the most common type) and CPV-2c (Goddard and Leisewitz, 2010; Greene and 
Decaro, 2011
b
) were discovered.  CPV-2 is presumed to have originated from FPV; CPV-
2a, b and c can infect cats, however FPV does not infect dogs (Goddard and Leisewitz, 
2010).  CPV infection has been associated with three main tissues, the gastrointestinal 
tract, bone marrow and myocardium.  There is a marked variation in clinical signs 
including parvovirus enteritis, neurological disease, cutaneous disease, myocarditis, and 
thrombosis.  The virulence of CPV-1 in dogs is uncertain, CPV-1 was thought to be non-
pathogenic before 1985 (Lamm and Rezabek, 2008, Goddard and Leisewitz, 2010).  
Vaccines against FPV/CPV are available (Table 1.1) and recommended in cats and dogs 
(Day, Horzinek and Schultz, 2011).  The gold standard for diagnosis of CPV or FPV 
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infection was electron microscopy (EM) on faeces and haemagglutination inhibition 
serological assays (HAI), however PCR has become increasingly available.  Cage side tests 
(e.g. SNAP® Parvo Test, IDEXX Laboratories, UK) are also available.  Treatment of cats 
and dogs is generally supportive; and rfeIFN- is licensed for treating CPV and FPV 
infection. 
 
1.2.5.2 Feline coronavirus 
Feline coronavirus is a large spherical, enveloped, positive sense single stranded (ss) RNA 
alphacoronavirus belonging to the family Coronaviridae.  As described above FCoV can 
be divided into two biotypes: FECV and FIP; FECV causes a mild self -limiting 
gastroenteritis mainly in kittens.  A recent study by Paris et al (2014) found a FECV 
prevalence of 56.9% in cats with clinical signs of gastroenteritis using real-time PCR.  
Prevalence of FECV has increased with more cats kept indoors, increasing the length of 
exposure to infected faeces (which would have been buried outdoors), and increased 
breeding of pedigree cats, which reduces genetic diversity and so results in a loss in 
immunity (Addie, 2011). 
 
Immunofluorescence to detect serological exposure to FECV can be carried out on blood; 
however titres are frequently slow to fall following viral clearance. Consequently, RT-PCR 
is increasingly used for detection of viral RNA in faeces.  Treatment of FECV is generally 
supportive.  Vaccine availability for FCoV is described above (Table 1.1). 
 
1.2.5.3 Canine coronavirus 
Canine coronavirus (CCoV) and FCoV are closely related, both of the alphacoronavirus 
genus, subgroup B.  A study by Decaro et al, 2010 found that recombinant CCoVs are 
circulating in dogs in different European countries.  Canine coronavirus can affect all dogs 
of all ages, which differs from CPV which usually affects dogs under two years.  The 
clinical signs of CCoV vary significantly; infected dogs usually have sudden onset 
diarrhoea preceded by some vomiting (Greene and Decaro, 2011
a
).  There is no sensitive 
gold standard diagnostic method for CCoV detection.  As with FCoV, treatment of CCoV 
is supportive and a vaccine is available (Table 1.1) however it is not recommended for 
routine use (Day, Horzinek and Schultz, 2011). 
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1.2.5.4 Cryptosporidium parvum 
Cryptosporidium parvum is an ubiquitous coccidian genus in the phylum Apicomplexa, 
family Cryptosporidiidae (Scorza and Lappin, 2011).  Cryptosporidium parvum is a 
zoonotic pathogen and is an important cause of gastroenteritis in a variety of animals; 
young and immunocompromised animals are more susceptible.  In immunocompromised 
humans C.parvum can be life-threatening (Higgins, et al 2001; Fontaine and Guillot, 2002; 
Tanriverdi et al, 2002).  Prevalence can be high, 24.4% of diarrheic cats were found to be 
infected by C.parvum by real-time PCR detection (Paris et al, 2014).  The traditional 
method of detection is a ZN (Ziehl-Neeslsen)-stained faecal smear, however PCR is now 
often used for diagnosis.  Treatment of C.parvum is generally supportive, with good 
nursing care.  
 
1.2.5.5 Giardia lamblia 
Giardia (also known as Giardia intestinalis, Giardia lamblia, or Giardia duodenalis) is the 
most commonly diagnosed gastrointestinal protozoan in the world, yet is poorly 
understood (Thompson, 2000).  Giardia infection can show no clinical signs, however 
younger, immunosuppressed animals, and those living in crowded environments can show 
clinical signs such as chronic diarrhoea and weight loss (Scorza and Lappin, 2011).  In cats 
the parasite can damage the small intestinal tract which can lead to maldigestion as well as 
malabsorption.  A recent study detected Giardia in 20.6% of diarrheic cats by real-time 
PCR (Paris et al, 2014).  In dogs there have been several studies using different diagnostic 
techniques giving a range of 13.0% to 19.04% (Itoh et al, 2001; Carlin et al, 2006; Olson et 
al, 2010).  Fenbendazole or metronidazole are regarded as the treatments of choice.  
 
1.2.5.6 Tritrichomonas foetus 
Tritrichomonas foetus is a highly motile flagellate protozoan parasite that resides in the 
large intestine of cats, and is distinct from other Tritrichomonas species and not considered 
to be zoonotic.  In the last 10 years it has emerged as a new and important cause of feline 
diarrhoea worldwide (Xenoulis et al, 2013).  Infection is most common in young cats from 
multi-cat households, particularly pedigree breeding catteries.  Clinical signs include 
frequent fetid diarrhoea, often with mucus, fresh blood and straining, but generally this is 
not severe.  Traditional diagnosis of infection is usually based on direct microscopic 
examination of culture (Gookin et al, 2002) of freshly voided faeces, however PCR testing 
is used more widely now (Gookin, 2011).   The treatment of choice is ronidazole, which 
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should be used with care as it is an unlicensed drug for cats with a narrow safety margin.  
Clinical signs are generally self-limiting in untreated cases, but may take months to 
resolve. 
 
1.2.5.7 Salmonella 
Salmonella spp. is a Gram-negative bacillus of the family Enterobacteriaceae.  Salmonella 
is an ubiquitous pathogen that infects a variety of mammals, birds, reptiles and insects, and 
is a potential zoonotic infection.  The clinical signs of Salmonella spp. are variable, 
diarrhoea can be watery to mucoid, with fresh blood present in severe cases, weight loss 
and dehydration are also common signs (Greene, 2011
b
).  Complications are rare but can 
occur; less than 10% of cats and dogs will die due to acute disease (Greene, 2011
b
).  The 
prevalence of the bacterium has been reported to be from one to 36% in healthy or 
hospitalised dogs, and one to 18% in healthy cats (Greene, 2011
b
).  Paris et al (2014) found 
that 0.8% of diarrheic cats were real-time PCR positive for Salmonella.  It is thought that 
cats may have natural immunity to Salmonella.  Kittens are more likely to be clinically 
affected than adult cats.  The standard detection method for Salmonella is bacterial culture.  
Treatment is generally supportive, antibacterial therapy may be indicated in severe illness. 
 
1.2.5.8 Campylobacter jejuni 
Campylobacter is a microaerophilic Gram-negative curved bacillus that causes 
gastroenteritis and is spread through contaminated food and water.  Campylobacter jejuni 
is the strain commonly associated with disease in cats, dogs and humans.  Infections in cats 
and dogs can often be asymptomatic, often seen with other infectious agents, and are 
usually seen in cats and dogs that are less than six months old (Fox, 2011).  There is a wide 
clinical spectrum of signs from mild loose faeces to bloody mucoid diarrhoea for five to 15 
days.  Campylobacter jejuni has been isolated from 21% of cats, and 29% of dogs with 
diarrhoea, but only in four percent of clinically healthy animals.  However prevalence data 
varies somewhat, some studies have found ranges of zero to 50% in healthy and ill cats 
(Fox, 2011).  The traditional method of detection is bacterial culture.  The effectiveness of 
antibacterial therapy in cats and dogs is unknown, however in severe disease it may be 
warranted (Fox, 2011). 
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1.2.5.9 Enterotoxigenic bacteria 
Clostridium perfringens and Clostridium difficile can cause canine diarrhoea.  These 
bacteria are normal constituents of the indigenous intestinal microflora and isolation rates 
are often similar in healthy and sick cats and dogs, therefore presenting great difficulties in 
determining their clinical significance (Marks, 2011).  Clinical signs are extremely 
variable, the severity can be mild and self limiting to potentially fatal.   
 
Clostridium perfringens is a Gram-positive spore-forming anaerobic rod.  Clostridium 
perfringens enterotoxin (CPE) is an important virulence factor for C. perfringens type A 
gastrointestinal disease in humans and dogs; however, the data implicating CPE in other 
animal diseases remains ambiguous.  PCR would be a useful tool in C.perfringens 
diagnosis as it can target the specific disease-causing toxin CPE gene.  Antibacterial 
therapy is indicated (Marks, 2011).   
 
Clostridium difficile is an anaerobic spore-forming Gram-positive rod.  Clostridium 
difficile is the most serious cause of antibiotic-associated diarrhoea (AAD) in humans and 
can lead to pseudomembranous colitis.  Clostridium difficile is resistant to most antibiotics 
and can therefore thrive when common antibiotics are used to treat other dog diseases.  
Toxins A and B (TcdA and TcdB) are thought to be the main virulence factors involved in 
canine C. difficile infection (Marks, 2011).  Toxin A has been shown to cause histological 
damage; in contrast TcdB shows no tissue damage.  Studies have suggested a synergistic 
effect of TcdA and TcdB, where the mucosal damage of TcdA enables the cytotoxic 
activity of TcdB (Marks, 2011).  Treatment is usually supportive, metronidazole is highly 
effective with little resistance reported (Marks, 2011). 
 
Escherichia coli (E.coli) is a Gram-negative rod-shaped bacterium that is commonly found 
in the lower intestine of warm-blooded organisms (endotherms).  The harmless strains of 
E.coli are part of the normal flora of the gut, and can benefit their hosts by producing 
vitamin K2, and by preventing the establishment of pathogenic bacteria within the 
intestine.  There are five known groups of diarrhoeagenic E. coli, of which 
enteropathogenic E. coli (EPEC), and enterotoxigenic E. coli (ETEC) have been associated 
with enteric disease in dogs, with samples being ST1 and ST2 (heat stable enterotoxin) 
positive but LT (heat labile enterotoxin) negative (Beutin, 1999).  As with C.perfringens 
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and C.difficile the ability of PCR to target the disease causing toxin genes ST1 and ST2 is 
highly advantageous.  Antibacterial therapy is indicated to treat dogs infected with 
enterotoxic E.coli.   
 
1.3 Polymerase Chain Reaction (PCR)  
The polymerase chain reaction (PCR) is a sensitive and specific method of detecting small 
amounts of nucleic acid in a biological sample, enabling a targeted sequence to be 
exponentially amplified (Mullis and Faloona, 1987).  The method of PCR has undergone 
many changes since its advent (Holland et al, 1991) and today the technique is used not 
just as a research tool, but as a diagnostic tool.  
 
The polymerase chain reaction requires the design of two oligonucleotides known as 
primers, a forward primer and a reverse primer, which are complementary and specific to 
the target sequence to be amplified; these primers should be designed from a conserved 
region of the target pathogen genome.  The PCR reaction requires several components; a 
heat-stable DNA polymerase enzyme such as Thermus aquaticus (Taq) polymerase, 
nucleotides, buffer, magnesium, primers and the template DNA (Figure 1.1).  PCR can 
only be carried out on DNA, so for RNA pathogens the RNA must first be transcribed into 
cDNA in a reverse transcriptase (RT) step.  The PCR reaction is carried out in a thermal 
cycler containing a thermal block that can be rapidly heated and cooled down.  Upon 
heating, double stranded DNA is denatured and split into single strands.  The temperature 
is then reduced to allow the specific primers to anneal to the single stranded DNA.  The 
Taq polymerase then enzymatically adds nucleotides, using the primers as template to 
assemble and extend a complementary strand of DNA.  Each copy of DNA can serve as a 
template for further amplification.  The cycle of heating and cooling is repeated 30 to 40 
times, doubling the PCR product with every cycle.  This is described in Figure 1.1.  
Therefore as each copy of DNA can act as a template in the next cycle, one copy of DNA 
can by multiplied into billions of copies over 30 to 40 cycles.  The PCR product is 
visualised by gel electrophoresis; DNA is separated by size using an electric current and 
viewed using ethidium bromide which fluoresces under ultraviolet light.  The sample PCR 
product is run with a DNA ladder (containing a series of DNA fragments of known base-
pair size).  A band at the expected base-pair size comparable to the positive control 
indicates a positive result, provided positive and negative controls have behaved as 
expected. 
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Polymerase chain reaction is more sensitive and rapid in comparison to traditional methods 
of detection, PCR is preferred for the detection of fastidious pathogens, therefore 
increasing overall detection rate, and is also useful to screen for newly discovered 
pathogens.  As well as more cases being associated to an aetiological cause, a new 
understanding of clinical syndromes has been developed, as previously undiagnosed or 
under-diagnosed pathogens are detected (Templeton et al, 2005; Gunson et al, 2008; 
Wolffs et al, 2011). 
 
In addition to using PCR to clinically diagnose the causative pathogen of the disease, the 
method can also be used to determine if the animal is “free from infection”, therefore 
detecting subclinical carriers, which can be important when introducing a cat or dog to a 
new home, prior to breeding, or for infection control when boarding, etc (Evermann, 
Sellon and Sykes, 2011).  Due to the high sensitivity of PCR, the presence of pathogen 
nucleic acid does not necessary indicate ongoing disease; therefore any PCR results must 
be interpreted carefully along with clinical signs of the animal.   
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Figure 1.1 The polymerase chain reaction 
 
 
The reaction is heated causing double stranded DNA to denature and split into single 
strands.  The specific primers are able to anneal to the single stranded DNA when the 
temperature is reduced.  Taq polymerase then enzymatically adds nucleotides, using the 
primers as template to assemble and extend a complementary strand of DNA.  Each copy 
of DNA can serve as a template for further amplification.  The cycle of heating and cooling 
is repeated 30 to 40 times, doubling the PCR product with every cycle.   
 
Image taken from University of Maine, 2013. 
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1.3.1 Real-time PCR 
Over the last 20 years PCR methods have been revolutionised, mostly so with the advent of 
real-time PCR, where the amplification of the PCR product is observed in real-time.  The 
exponential increase in product is seen as an increase in fluorescence, measured by a 
photo-detector in a real-time PCR instrument.  The PCR reaction can take place and be 
measured in a single tube with no need for further analysis; referred to as a ‘closed tube 
technique’.  Several real-time PCR chemistries exist; some use a specific probe in addition 
to specific primers, which increases the specificity of the reaction.  This probe is labelled 
with a fluorescent dye and a quencher dye and is designed to bind to an internal region of 
the PCR product. 
 
In real-time PCR, fluorescence increases every PCR cycle, when and how this occurs 
varies with the chemistry used.  The increase in fluorescence released every cycle results in 
an overall exponential increase in fluorescence which can be plotted in a graph (Figure 
1.2).  The point at which the sample becomes positive is called the cycle threshold (Ct), 
this is when the fluorescence becomes detectable above the background.  As the Ct value is 
directly related to the starting target copy number, the Ct value is semi-quantitative.  A low 
Ct value indicates a strong positive (less cycles required for the fluorescence to rise 
appreciatively above the background), whereas a high Ct values indicates a weak positive 
(with many cycles required before fluorescence is appreciatively increased above the 
background).  The assay can be made fully quantitative by running a set of known 
standards, a 10-fold dilution series of standards of known quantity, alongside the test 
samples creating a standard curve.  The Ct values of unknown samples can be measured 
against the standard curve of the standards giving a quantification value for that sample.  
This is particularly useful when the viral load may help with clinical diagnosis, disease 
progression and treatment, for example the stage of FIV infection (Diehl et al 1996). 
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Figure 1.2 An exponential amplification 
curve.  
 
The point at which the sample becomes positive is called the cycle threshold (Ct), this is 
when the fluorescence becomes detectable above the background. 
 
Image taken from Heid et al, 1996. 
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As mentioned above there are a number of chemistries available for real-time PCR, 
specific methods include dual-labelled probes such as TaqMan probes (also known as 
hydrolysis or 5’ nuclease probes), molecular beacons and minor groove binders (which can 
be TaqMan probes or Eclipse probes), dual hybridisation probes, fluorescent labelled 
primers such as Scorpion primers and Lux primers, and DNA binding dyes such as SYBR 
green.   
 
1.3.1.1 Dual labelled probes 
Dual labelled probes are designed to hybridise to an internal region of a PCR product.  
TaqMan probes are dual labelled probes which have a fluorescent dye attached to the 5’ 
end and a quencher attached to the 3’ end of the probe.  While the probe is intact, the 
fluorescent dye is quenched by the quencher dye.  TaqMan PCR utilises the 5’→3’ 
exonuclease activity of Taq polymerase (Figure 1.3).  As with traditional PCR the DNA is 
denatured by heating, when the reaction is cooled the primers and probe then anneal to the 
single stranded DNA, as the Taq polymerase extends the strand 5’→3’, it cleaves the 
probe, separating the fluorescent dye and quencher dye, causing the probe to fluoresce.  
Fluorescence increases in each cycle, proportional to the rate of probe cleavage.  Minor 
groove binder (MGB) probes have a fluorescent dye at the 5’ end and MGB on the 3’end, a 
MGB is a non-fluorescent quencher which allows the real-time PCR instrument to measure 
the reporter dye more precisely.  In addition the MGB increases the melting temperature of 
the probe, allowing the use of shorter probes.  Although MGB probes offer advantages, 
they are much more expensive than non-MGB probes, and they are available with limited 
fluorescent dyes. 
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Figure 1.3 Overview of TaqMan probe based chemistry 
 
TaqMan PCR utilises the 5’→3’ exonuclease activity of Taq polymerase.  The DNA is 
denatured by heating, the primers and probe then anneal to the single stranded DNA when 
the temperature is reduced. As the Taq polymerase extends the strand 5’→3’, it cleaves the 
probe, separating the fluorescent dye and quencher dye, causing the probe to fluoresce.  
Fluorescence increases in each cycle, proportional to the rate of probe cleavage.   
 
Image taken from Life Technologies, 2014a
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1.3.1.2 Molecular beacons 
Molecular beacons like TaqMan probes also have a fluorescent and quencher dye attached, 
however unlike TaqMan probes, molecular beacons are designed to remain intact during 
the amplification reaction.  A molecular beacon has a hairpin like structure with 
fluorescent and quencher attached, when the molecular beacon binds to the target DNA the 
probe becomes linear and so the fluorescent and quencher dyes become separated causing 
the fluorescent probe to fluoresce.  
 
1.3.1.3 Dual-hybridisation probes 
Dual-hybridisation probes have two specific primers, and also two specific probes – a 
donor and an acceptor probe.  The probes are labelled with a pair of dyes that exhibit 
fluorescence resonance energy transfer (FRET).  The donor dye is attached to the 3' end of 
the first probe, while the acceptor dye is attached to the 5' end of the second probe.  They 
bind the template DNA adjacent to each other, during this annealing step when the probes 
are fully hybridised FRET occurs from the donor to the acceptor probe and fluorescence is 
released. 
 
1.3.1.4 Fluorescent-labelled primers 
Fluorescent-labelled primers exist in several forms, for example Scorpion primers, Lux 
primers.  Scorpion Primers have a reporter and quencher dye and the primer is in a stem-
loop formation.  Unlike molecular beacons, the primer anneals to target DNA with the 
stem-loop intact, it is during the extension step that the quencher is separated from the 
reporter and fluorescence is released. 
 
1.3.1.5 DNA-binding dyes  
DNA-binding dyes used in real time PCR, such as SYBR GREEN is a real time method in 
which the dye binds to all double stranded DNA in a sample, therefore it may bind to non-
specific dsDNA.  As the PCR progresses, more PCR product is created. SYBR® dye binds 
to all double-stranded DNA, so the result is an increase in fluorescence intensity 
proportioned to the amount of PCR product produced.  Good design of primers and melt 
curve analysis improves specificity, as the melting temperature should be specific to the 
target sequence. 
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1.3.2 Benefits and limitations of real-time PCR 
Real-time PCR is an extremely sensitive and specific method of pathogen detection and the 
use of a specific probe further increases the specificity.  The closed system of real-time 
PCR lends the technology to automation (extraction and plate set-up) which increases 
rapidity, leading to reduced turn-around times and overall costs.  The standard parameters 
of real-time PCR also allows several PCR assays to be multiplexed, as all types of 
pathogens, DNA or RNA can be tested using the same cycling conditions and PCR kit 
(Gunson, Collins, and Carman, 2006). 
 
As mentioned above a benefit of replacing traditional detection methods with real-time 
PCR is that it lends itself to automation, so making it easier for the laboratory to become 
automated, from sample receipt, to sample extraction, through to PCR set-up, analysing of 
results and uploading of results onto a laboratory database for reporting.  Unlike traditional 
methods, PCR does not require live virus for detection, therefore samples are easily 
transported, and samples can be added to lysis buffer (lysis of the cells rendering the virus 
non-infectious) and kept at room temperature.  Samples can arrive in the laboratory in the 
correct vial to be loaded directly onto the extraction platform; if these samples are also 
labeled with a unique barcode then the extraction platform can scan and record the samples 
extracted.  The tests required for the samples can be inputted into a laboratory database 
(laboratory information management system (LIMS), allowing automated real-time PCR 
setup of the appropriate samples with the requested test.  Samples are then amplified and 
once results are analysed (which can be manually done or automatically carried out), then 
results can be uploaded to the laboratory database for reporting.  This greatly reduces 
hands-on time, turnaround times, costs, and the opportunity for human error. 
 
As mentioned above, one of the major advantages of real-time PCR is that it is highly 
sensitive; however this can be at times a disadvantage.  Due to real-time PCR being able to 
amplify and detect just one copy of DNA, it is possible that a pathogen may be detected 
that is not causing disease, for example low level residual DNA from a past infection may 
be detectable if an animal is shedding virus.  Also, if an animal has been recently 
vaccinated, this should be taken into account when interpreting results as recent 
vaccination may lead to a PCR signal due to residual nucleic acid from the vaccine.  
 25 
Therefore a weak positive result, for example a Ct greater than 35 (very weak positive), 
must be considered along with clinical signs as this may not be the cause of disease. 
 
1.3.3 Multiplex real-time PCR 
Although all PCR methods can be multiplexed, real-time PCR tends utilises the same 
reaction conditions (more so than traditional PCR protocols) and so lends itself readily to 
multiplexing.  Assays can be multiplexed in order to detect more than one target 
simultaneously in one reaction well.  For example the availability of five different channels 
on the ABI Prism 7500 SDS real-time platform (Applied Biosystems, Warrington, UK) can 
allow 96 samples/controls to be screened for four to five pathogens in one test.  Multiplex 
assays can be designed along syndromic lines, offering users a single test to investigate a 
specific set of clinical signs, for example. respiratory disease.  This prevents sequential 
testing and offers all results at the same time.  For human diagnostics these ‘menus’ of 
screens have improved rapidity, cost, ease of use and throughput of the diagnostic service 
(Gunson et al, 2008). 
 
The ability to detect the main causes of a disease syndrome in one sample, whether viral, 
bacterial, parasitic or fungal, is a tremendous benefit to a veterinary practitioner for rapid, 
“all in one” results.  This will allow the treating veterinary practitioner to make a clinical 
decision in a timely manner that could influence the outcome for the animal.  In addition, 
multiplexing would be greatly advantageous to the veterinary laboratory to reduce costs 
and turnaround times. 
 
Few veterinary laboratories offer multiplex real-time PCR, most use single assays for each 
pathogen, and currently no commercial companies supply multiplex kits.  The use of 
multiplex real-time PCR in the veterinary laboratory would allow for simultaneous testing 
of multiplex infectious pathogens from one sample in as little as three hours.  As outlined 
above in section 1.2.5 possible causes of feline gastroenteritis include FPV, FCoV, 
Salmonella, C.jejuni, C.parvum, Giardia and T.foetus.  In order to detect these pathogens 
by current methods, virus isolation, bacterial culture, ZN staining, zinc sulphate floatation 
and PCR would need to be carried out.  Each of these methods requires a different set of 
specialist technical skills, and setting up each method can be labour intensive and costly.  
However this panel of seven pathogens can be tested rapidly and simultaneously using one 
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method: multiplex real-time PCR.  In addition, multiplex real-time PCR easily allows the 
incorporation of an internal control (IC) assay.  An IC is the ideal positive control as it 
allows for monitoring of sample inhibition, extraction failure and PCR set-up failure.  
Nucleic acid extraction and screening of the sample using two or three multiplex real-time 
PCR assays can be done in less than three hours to determine the causative agent or agents, 
allowing for timely clinical intervention (Gunson et al, 2008).  In addition, several probes 
can be labeled with the same dye to increase the level of detection further, for example in 
human diagnostics coronaviruses NL63, 229E and OC43 can be labeled with the same dye, 
leaving other channels available for different pathogens, for example rhinovirus and 
adenovirus. 
 
As well as being semi-quantitative, real-time PCR can be designed to quantify, subtype, or 
even resistance test a particular pathogen.  Consequently novel in-house methods can be 
designed to diagnose, type and quantify.  Therefore as well as replacing “gold standards” 
that may not be sensitive or specific, multiplex real-time PCR can also replace the need for 
traditional nucleic acid sequencing, which significantly reduces turnaround times and 
costs.  Multiplex PCR can also be used for large scale prevalence and epidemiology studies 
of cats and dogs, and for testing of archived samples, allowing retrospective analysis of 
samples. 
 
However developing multiplex assays is not just a case of adding assays together.  The 
assay must be carefully optimised to ensure that multiplexing does not result in a loss of 
sensitivity or specificity in comparison to the single test.  A multiplex assay also requires 
careful optimisation to ensure that no crosstalk is evident; the ABI 7500 real-time PCR 
instrument has five channels therefore theoretically five different targets can be detected in 
one well (Figure 1.1).  However, this is not always achievable, as it is possible for the 
fluorescence increase with one dye to ‘spill over’ into another channel, resulting in 
‘crosstalk’.  This leads to what appears to be two positive results, one of which is a false 
positive.  Crosstalk can be eliminated by carefully optimising the probe concentrations in 
the multiplex, for example by reducing the concentration of the probe that is crosstalking 
into the other channel.  In addition to crosstalk, cross-reaction can affect the sensitivity and 
specificity of a multiplex assay.  This is because cross-reaction between primers and 
probes from different assays can occur; this is also called primer-dimer formation. 
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Another way in which multiplexing can result in a loss of sensitivity is through 
competition for PCR reagents.  Multiplexing can create competition in a mixed infection 
between targets where a stronger positive out-competes a weaker positive, resulting in a 
false negative result.  The stronger target in the sample has more DNA to begin with and so 
uses up all of the PCR reagents quickly, the target with less starting material is not able to 
amplify enough to show a rise in fluorescence due to the lack of reagents available in the 
presence of a stronger target.  In many sample types, including respiratory and faecal, 
mixed infections can be expected, therefore it is important to be able to detect all potential 
disease-causing pathogens in a sample.  In any sample containing an IC, a positive sample 
is effectively a mixed infection; therefore competition could result in a sample being 
falsely inhibited, or the IC could outcome a positive sample, resulting in a sample being 
false negative.  Competition can be overcome by careful optimisation, by reducing one or 
both of the primers and/or probes that are cross-reacting, and by the use of PCR kits 
specially designed for use with multiplex primer and probe pools.  However care must be 
taken to ensure that any changes to the concentration of each component of the assay does 
not affect the overall efficiency and sensitivity of the assay.  There are now commercially 
available PCR kits specifically designed for use with multiplex assays, which can help 
reduce crosstalk, cross-reaction and competition.   
 
Once a multiplex assay has been designed, optimised, and evaluated to assess the endpoint 
detection limit, specificity and robustness, the assay must the be evaluated to determine the 
clinical sensitivity and specificity of the assay.  Ideally, clinical validation comparing the 
multiplex assay to a “gold standard” for each pathogen should be carried out.  This is a 
large scale evaluation where the multiplex assays are run in parallel to a gold standard and 
the results compared.  This gives the clinical sensitivity and specificity of the multiplex 
and if planned properly can determine negative and positive predictive values with 
prevalence data.  It should be noted that completing the clinical validation of the feline and 
canine multiplex assays is beyond the timescale of this research project, however 
preparations to carry out the validations have been made.  This project aims to assess the 
analytical components of the multiplex assays as a measure of the test performance of the 
multiplex panels. 
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Although introducing a streamlined, automated multiplex real-time PCR diagnostic service 
will significantly reduce turn-around times, time, labour time and overall costs, I should be 
noted that the initial implementation of such a service is expensive.  In addition staff must 
be trained to develop and run the service, including troubleshooting assay problems, and 
importantly to ensure quality control of the service. 
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1.4 Aim of research 
Although PCR is becoming more readily available, the use of real-time PCR in veterinary 
diagnostic laboratories is not currently widespread, and many laboratories still use 
traditional detection methods.  The implementation of an internally controlled real-time 
multiplex PCR would allow for rapid detection of a variety of pathogens, which will in 
turn aid in the treatment and clinical management of the animal, and increase our 
understanding of infectious disease in cats and dogs.  The aim of this project is to begin the 
development of a panel of internally controlled in-house designed syndrome based 
multiplex real-time PCR assays for the detection of infectious disease in cats and dogs.  
The panels developed will screen for feline respiratory disease in throat swab samples, 
feline conjunctivitis in eye swab samples, feline anaemia in blood samples, feline gingivitis 
in blood and swab samples, and feline and canine gastroenteritis in faecal samples.  The 
assays will be optimised and assessed as single real-time PCR assays and then multiplexed 
together.  The evaluation of the multiplexes will include assessing the robustness of the 
multiplexes by direct sensitivity comparison to the single assays, the endpoint detection 
limit of each target in the multiplex, the specificity, and the repeatability and 
reproducibility of the assay. 
 
This project aims to assess the analytical components of the multiplex assays as a measure 
of the test performance of the multiplex panels.  If successful, the in-house designed 
multiplex real-time PCR assays will replace conventional methods currently available and 
enable the veterinary clinician to screen a clinical sample for multiple pathogens causing a 
specific clinical syndrome with minimal tests. 
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CHAPTER 2  
2. Methods Introduction 
This chapter details the methods used to develop the in-house designed multiplex assays.  
The MIQE guidelines (Bustin et al, 2009) for the development of in-house molecular 
assays provide recommendations on what is required in order to validate in-house assays.  
These guidelines were used in this study as a basis for the evaluation of each assay.  
Section 2.1 describes the selection of a nucleic acid extraction platform, a real-time PCR 
kit, a real-time PCR instrument, the selection of significant pathogen targets, real-time 
PCR assay selection and the design of the multiplex assays.  Section 2.1 also includes the 
general laboratory methods used in the development of the multiplex assays.  In Section 
2.2, the methods used to optimise each multiplex primer-probe pool are described, together 
with the assessment of the sensitivity, specificity and robustness of each multiplex assay.   
 
2.1 Methods common to all multiplex assays 
2.1.1 Nucleic acid extraction platform 
The first stage in developing an in-house real-time multiplex panel of tests is to choose a 
nucleic acid extraction method.  There are many methods available for the extraction of 
nucleic acid from clinical samples, including manual methods, semi-automated and fully 
automated extraction platforms.  These methods can extract DNA or RNA, and in some 
cases total nucleic acid, from numerous sample types. 
 
Manual extraction is highly labour intensive and not suitable for high-throughput 
laboratories; in addition, the separate washing and spinning/vacuum steps present an 
increased risk of contamination.  For these reasons manual extraction was not considered 
for this project.  Many automated and semi-automated platforms are available.  Automated 
platforms offer rapid extraction with high throughput and little hands-on time, which 
although expensive to implement initially, can significantly reduce overall testing costs.  In 
the laboratory where the project is being carried out, the West of Scotland Specialist 
Virology Centre (WoSSVC, Glasgow), the MDX (Qiagen, Germany), M2000 (Abbott, 
USA) and the easyMag (BioMérieux, France) extraction platforms are in use. 
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The Qiagen MDX and the Abbott M2000 can extract 96 samples in two to three hours, 
which is exceptionally fast and ideal for high through-put laboratories.  However, there are 
some limitations with these platforms.  Firstly, different extraction kits are recommended 
for viruses and bacteria (MDX), or for RNA and DNA (M2000).  Secondly, all samples on 
an extraction run must have the same input and output volumes, and a dead volume for 
each sample, for example the MDX requires a 500µl sample volume for nucleic acid 
extraction however the instrument only uses 263µl of the sample.  For this study, as the 
multiplex panels contain both RNA and DNA pathogens, a mix of viruses, bacteria and 
parasites, and a variety of sample types, a platform that enables complete nucleic 
extraction from all sample types is required.  Therefore the bioMerieux easyMag was 
chosen as the extraction platform (Figure 2.1).  This is a semi-automated extraction 
platform for the purification and concentration of total nucleic acids (RNA and DNA) from 
all types of biological specimens.  Different sample volumes can be accommodated, 
negating the requirement for a dead volume, and the nucleic acid can be eluted into 
different volumes on the same run, making this platform ideal for variable sample types.  
Moreover, it has been shown to work for viruses, bacteria and parasites without needing 
multiple diverse extraction kits.  The throughput of 24 samples/controls per run in less than 
45 minutes is ideal for the throughput of the intended laboratory (Glasgow Veterinary 
Diagnostic Services (GVDS), School of Veterinary Medicine, University of Glasgow).  
The method is based on a generic method for binding nucleic acids from complex 
biological samples to magnetic silica (Boom et al, 1990).  The sample is mixed with a lysis 
buffer containing a chaotropic agent (guanidinum thiocyanate).  Any cellular material, 
viruses, fungi, parasites or bacteria present in the sample will be lysed and the nucleic acid 
released.  The lysis buffer inactivates any nucleases present in the sample.  The isolation 
process is initiated by the addition of magnetic silica to the lysed sample.  Nucleic acids 
present in the lysate will bind to the magnetic silica under the high salt conditions.  The 
magnetic silica is then washed several times using two wash buffers to improve 
purification.  Next, the nucleic acids are released (eluted) from the magnetic silica and 
concentrated in a specified volume of the elution buffer.  This elution process is 
accelerated by flushing the magnetic silica in the elution buffer at an elevated temperature.  
Finally the magnetic silica is separated from the elution buffer before the concentrated 
nucleic acid solution is available for collection.  For the samples used in the assessment of 
the multiplexes the standard easyMag protocol was followed according to the 
manufacturer’s instructions.  Nucleic acids were extracted from 200µl sample, and eluted 
into a final volume of 110µl.  All reagents were supplied by BioMérieux. 
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2.1.2 Real-time RT-PCR kit 
The next stage is to choose an appropriate real-time PCR kit.  Many kits are commercially 
available for real-time PCR.  These kits contain all the reagents needed to carry out PCR 
(e.g. reaction buffer, Taq polymerase enzyme, RT enzyme if RT-PCR) with the exception 
of the pathogen specific primers and probes.  RT-PCR was originally a two-step reaction 
with the RT step being carried out separately prior to PCR, now one-step RT-PCR kits are 
available where the RT enzyme is added to the PCR mastermix (containing reaction buffer, 
magnesium, etc.), and the RT step occurs prior to the PCR, but in the same reaction.  A 
one-step reaction is optimal for reduced hands-on time and reduced risk of contamination.  
Usually, separate kits are used for DNA and RNA targets, although some RT-PCR kits can 
also be used to detect DNA pathogens (Gunson et al, 2008), which is ideal for multiplex 
assays that contain both RNA and DNA targets.  Recently PCR kits have been designed to 
use specifically with multiplex assays.  These are RNA or DNA kits and aim to reduce 
cross-reactions between primers and probes, crosstalk between dyes, and competition 
between targets.  Some kits have been assessed internally at the WoSSVC and it was found 
that these kits were prone to non-specificity, resulting in false positive results (Rory 
Gunson, personal communication, 2010).  These kits were not considered in this study. 
 
As most of the multiplexes are likely to contain at least one RNA pathogen (Table 1.1), for 
ease of use, a one-step RT-PCR kit was chosen as the basis for all assays.  The kit chosen 
to assess the multiplex development was the AgPath-ID One-step RT-PCR kit 
(Ambion/Life Technologies, Paisley, UK), that is suitable for both RNA and DNA.  This 
kit has been assessed in the WoSSVC with human diagnostic multiplex screens.  When 
compared to a similar one-step RT-PCR kit by Invitrogen (SuperScript® III One-Step RT-
PCR System with Platinum® Taq DNA Polymerase) that has been in use in the laboratory 
for 10 years, the Ambion kit was found to be as sensitive as the Invitrogen kit at the 
endpoint of detection (Rory Gunson, personal communication, 2010).  In addition the 
Ambion kit was found to perform better than the Invitrogen kit when a mixed infection or 
IC was present in a sample; therefore competition was reduced with the Ambion kit (Rory 
Gunson, personal communication, 2010). Based on these data, the Ambion kit was chosen.  
In this study, RT-PCR was performed on 6µl of template nucleic acid in a 15µl reaction 
and the following thermal profile: 50ºC for 15 minutes (RT step); 95ºC for 10 minutes; and 
then 40 amplification cycles of 95ºC for 8 seconds and 60ºC for 34 seconds.  Reaction 
volumes were modified in-house (Gunson, Collins, and Carman, 2006).  
 34 
Figure 2.1 The BioMérieux easyMag extraction platform 
 
 
Image taken from BioMérieux, 2014. 
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2.1.3 Real-time PCR instrument 
The RT-PCR was carried out on an ABI 7500 real time PCR instrument as these were the 
established instruments in the laboratory (Figure 2.2).  The ABI Prism 7500 platform has 
five channels which can detect different fluorescent dyes; this allows the multiplexing of 
PCR assays by labelling each probe with a different detector dye (Figure 2.3).   
 
2.1.4 Pathogen selection 
The next step was to determine which pathogens to include in each panel.  Pathogens of 
importance in feline and canine infectious disease were identified by searching the 
literature and consulting with veterinary practitioners and veterinary microbiologists at the 
School of Veterinary Medicine, University of Glasgow.  The pathogens selected are 
outlined in Table 2.1. 
 
2.1.5 Real-time PCR assay selection  
The next step was to choose assays from the literature that could detect the targets outlined 
in Table 2.1.  When developing a multiplex assay a researcher can choose to either design 
their own assays from scratch or choose a published assay from the literature.  Designing a 
real-time assay from scratch requires significant experience and can be costly and time 
consuming.  Knowledge and experience of the different software programs required for 
real-time PCR design is also essential (such as BLAST® (Altschul et al, 1990), and Primer 
Express® (Life Technologies, Foster City, USA).  In addition, an in-depth knowledge of 
the genome of the pathogen of interest is required, to know where to best target a new 
assay.  The newly designed assay will also have to be extensively evaluated as there will 
be no data to support its performance.  Choosing a published assay has a great number of 
advantages over designing an assay from scratch.  It is likely that any published real-time 
PCR assays have been developed and evaluated by research groups that specialise in a 
particular pathogen and therefore the assay will have already been validated extensively.  
As a result the researcher can choose a published assay with confidence of its sensitivity 
and specificity.  Although it is important to note that not all published assays are well 
validated and so care should be taken when selecting published assays.  For this project the 
assays came from two sources: assays already in use at GVDS, and assays published in the 
literature.  
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Figure 2.2 The ABI Prism 7500 SDS real-time platform  
 
Image taken from Life Technologies, 2014b 
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Figure 2.3 The ABI 7500 Prism spectra 
 
 
The ABI 7500 has five channels which can detect up to five different fluorescent dyes; 
FAM, VIC/HEX, TAMRA, ROX and Cy5.  Probes can be labelled with different dyes and 
so can be distinguished from each other in a multiplex. 
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Table 2.1 Selected pathogens and in-house multiplex design  
Screen Multiplex components 
Feline Respiratory  feline herpesvirus, feline calicivirus, Bordetella bronchiseptica, internal control (mumps virus) 
Feline Conjunctivitis feline herpesvirus, Chlamydophila felis, Mycoplasma felis, internal control (herpes simplex virus-1) 
Feline Anaemia Anaemia 1 feline leukaemia virus, feline immunodeficiency virus, feline coronavirus  
Anaemia 2 haemoplasmas, internal control (mumps virus) 
Feline Gingivitis  feline leukaemia virus, feline immunodeficiency virus, feline calicivirus, internal control (mumps virus) 
Feline/Canine 
Gastroenteritis 
Gastroenteritis 1 parvovirus, internal control (mumps virus) 
Gastroenteritis 2 coronavirus, Salmonella, Campylobacter jejuni 
Gastroenteritis 3 Cryptosporiduim parvus, Giardia, Tritrichomonas foetus 
Gastroenteritis 4* Clostridum perfringens (toxin CPE), Escherichia coli (toxin ST1), Clostridium difficile (toxins A and B) 
* Canine only.  
3
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2.1.5.1 Existing assays in use at Glasgow Veterinary Diagnostic Service 
The GVDS currently use validated singleplex real-time PCR assays for FHV, M. felis, and 
FCoV.  The M. felis assay is based on a conserved region of the genome identified by 
Chalker et al (2004), the primers and probe were designed at the GVDS; the FCoV assay 
was modified from the assay published by Gut et al (1999) and the FHV assay was 
designed in-house.  These assays have been fully validated and were found to be at least as 
sensitive as the traditional method (data not shown).  The primer and probe sequences for 
these assays are given in Table 2.2 
 
2.1.5.2 Published assays in the literature 
The literature was searched for real-time TaqMan PCR assays for the remaining targets.  
Where more than one assay was published, the validation data was compared and the most 
validated assays (i.e. sensitivity and specificity assessed) were chosen.  The primer and 
probe sequences and published sources for the selected assays are given in Table 2.2.  For 
each primer and probe, the theoretical sensitivity and specificity was confirmed using 
BLAST.  BLAST allows the comparison of a sequence, such as a primer or probe 
sequence, to a library of sequences that have been uploaded onto the database by research 
groups from around the world.   
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Table 2.2 Selected real-time PCR assay primer-probe sequences with dyes 
Target Forward primer Reverse primer Probe Reference 
Feline herpesvirus TGG TGC CTA TGG AAT AGG TAA GAG TT GTC GAT TTT CAT CCG CTC TGA FAM-AAC GGC GAA GTA CC-MGB GVDS 
Feline calicivirus GTA AAA GAA ATT TGA GAC AAT TAC TGA AGW TCG CGY CT HEX- CAA ACT CTG AGC TTC GTG CTT AAA-BHQ Abd-Eldcum et al , 2009 
Bordetella bronchiseptica  ACT ATA CGT CGG GAA ATC TGT TTG CGT TGT CGG CTT TCG TCT G CY5-CGG GCC GAT AGT CAG GGC GTA G-BHQ Helps, Lait, and Damhuis, 2005 
Mycoplasma felis GTG GGG ATG GAT TAC CTC GGA CTA TTA TCA AAA GCA CAT AAC HEX-CTA CGG AGT ACA AGT TAC AAT TCA-BHQ GVDS  
Chlamydophila felis GAA CTG CAA GCA ACA CCA CTG   CCA TTC GGC ATC TTG AAG ATG CY5-CGC TGC CGA CAG ATC AAA TTT TGC C-BHQ Helps, Lait, and Damhuis, 2005 
Parvovirus ACT GCA TCA TTG ATG GTT GCA GGT ATG GTT GGT TTC CAT GGA FAM- CCC AAT GTC TCA GAT CTC ATA GCT GCT 
GG-BHQ 
Meli et al , 2004 
Salmonella CTC ACC AGG AGA TT AC AA CA TGG AGC TCA GAC CAA AAG TGA CCA TC HEX- CAC CGA CGG CGA GAC CGA CTT T-BHQ PC 
Campylobacter jejuni TGG TGG TTT TGA AGC AAA GAT T AAT ACC AGT GTC TAA AGT GCG TTT 
AT 
CY5-TTG AAT TCC AAC ATC GCT AAT GTA TAA 
AAG CCC TTT-BHQ 
PC 
Coronavirus GAT TTG ATT TGG CAA TGC TAG ATT T AAC AAT CAC TAG ATC CAG ACG TTA 
GCT 
FAM-TCC ATT GTT GGC TCG TCA TAG CGG A-BHQ GVDS (modified from Gut et al  
1999) 
Giardia GAC GGC TCA GGA CAA CGG TT TTG CCA GCG GTG TCC G ROX-CCC GCG GCG GTC CCT GCT AG-BHQ PC 
Tritrichomonas foetus GCG GCT GGA TTA GCT TTC TTT GGC GCG CAA TGT GCA T VIC-ACA AGT TTC GAT CTT TG-MGB McMillen and Lew, 2006 
Cryptosporidium parvum CTT CAC GTG TGT TTG CCA AT CCT TTT CAT GAC TTG TCT TAT CAG G CY5-CCA ATC ACA GAA TCA TCA GAA TCG ACT 
GGT ATC-BHQ 
PC 
4
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Target Forward primer Reverse primer Probe Reference 
Clostridium perfringens 
toxis  
AAC TAT AGG AGA ACA AAA TAC AAT AG TGC ATA AAC CTT ATA ATA TAC ATA 
TTC 
FAM-TCT GTA TCT ACA ACT GCT GGT CCA-BHQ Gurjar et al  2008 
Escherichia coli toxin  CTG GTT TTG ATT CAA ATG TTC GTG TTC TGA GGG AAA GGT GAA AAA GAC HEX- TTG ATT TCT TCA TAT TAC CTC CGG ACA 
TGG CA-BHQ 
Hardegen et al  2010 
Clostridium difficile 
(Toxin B only) 
GAA AGT YCA AGT TTA CGC TCA AT GCT GCA CCT AAA CTT ACA CCA  Cy5-ACA GAT GCA GCC AAA GTT GTT GAA TT-
BHQ 
Van den berg et al  2007 
Feline leukaemia virus AAC AGC AGA AGT TTC AAG GCC TTA TAG CAG AAA GCG CGC G FAM- CCA GCA GTC TCC AGG CTC CCC A-BHQ Tandon et al , 2005 
Feline immunodeficiency 
virus  
CCA TCG AAC GTC TGC CCT A TCA CCC GTG GTC ACC ATG HEX- CGA TGG TGG TCG CCG TGC CTA-BHQ Ryan et al , 2003 
Mycoplasma haemofelis GTG CTA CAA TGG CGA ACA CA TCC TAT CCG AAC TGA GAC GAA FAM- TGT GTT GCA AAC CAG CGA ATG GT-BHQ Peters et al , 2008 
Mycoplasma 
haemominutum 
TGA TCT ATT GTK AAA GGC ACT TGC T TTA GCC TCY GGT GTT CCT CAA HEX- TTC AAT GTG TAG CGG TGG AAT GCG T-
BHQ 
Peters et al , 2008 
Mycoplasma turicensis AGA GGC GAA GGC GAA AAC T CTA CAA CGC CGA AAC ACA AA Cy5-CGT AAA CGA TGG GTA TTA GAT GTC GGG 
AT-BHQ 
Peters et al , 2008 
RNA internal control 
(mumps virus) 
TCT CAC CCA TAG CAG GGA GTT ATA T GTT AGA CTT CGA CAG TTT GCA ACA 
A 
ROX-AGG CGA TTT GTA GCA CTG GAT GGA ACA-
BHQ                     
Uchida et al , 2004 
DNA internal control 
(human herpesvirus-1) 
TCC TSG TTC CTM ACK GCC TCC C GCA GIC AYA CGT AAC GCA CGC T ROX- CGT CTG GAC CAA CCG CCA CAC AGG T-
BHQ 
Van Doornum et al , 2003  
PC: Personal communication with Miriam Steiner, 2010.  GVDS: Glasgow veterinary diagnostic service.
4
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2.1.6 Internal control selection 
The next step is to select an internal control (IC) to use in each multiplex.  An IC is the 
ideal positive control in real-time PCR.  The IC should be suited to the target i.e. an RNA 
IC should be used if the target is an RNA pathogen, so that the IC is also controlling the 
RT step.  Internal controls exist in different forms, some controlling the whole extraction 
and PCR process whereas some only control the PCR stage.  The IC used in the multiplex 
panels will assess the whole process from extraction through to PCR.  The IC will be 
added to each sample at the extraction phase, and will be a pool of a DNA and RNA IC.  
The IC will therefore monitor inhibition in the sample, PCR inhibition and PCR set-up 
error for DNA and RNA pathogens. 
 
In this study we used herpes simplex virus-1 (HSV1) as a DNA IC.  For the RNA IC, 
mumps virus was used.  Both viruses are ideal ICs as they will not be present in the sample 
population being tested, and BLAST searches were carried out to ensure that the primers 
and probes did not cross-react with any of the feline or canine assays.  Since both are 
readily cultured, including at the WoSSVC, large batches of IC can be manufactured 
locally at a low cost in comparison to a commercially available IC.  Each syndromic panel 
has an IC assay incorporated into the multiplex assay.  If there was more than one 
multiplex assay for a particular syndrome (e.g. the gastroenteritis panel has four multiplex 
assays), an IC was added to one of the multiplexes, e.g. GE1 for the gastroenteritis panel 
(Table 1.1). 
 
In practice, the pooled HSV1/mumps virus IC was added to each sample prior to extraction 
by adding a set volume to each easyMag reaction vessel.  The Ct of the IC in each sample 
was then compared to the expected Ct to determine whether inhibition/error had taken 
place.  Several extraction runs of samples containing the IC are assessed to give a reliable 
expected output Ct value prior to routine use.  
 
2.1.7 Multiplex panel design and choice of fluorescent dyes for probes 
The multiplexes were designed based on the chosen pathogens and combinations outlined 
in Table 2.1, and fluorescent dyes were applied to each probe.  The dyes ascribed to each 
probe are outlined in Table 2.2.  The preferred dyes for triplex assays are FAM, VIC/HEX 
and Cy5 (Figure 2.1).  These dye combinations work on most assay platforms and are 
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commonly used by researchers.  For fourplex PCR we used the dye ROX.  The ROX dye is 
often used as a background/reference dye with some PCR kits.  However this dye can be 
used as a fluorescent dye for a probe like FAM, VIC etc, as long as the PCR kit contains 
no ROX as a reference dye.  The combination of FAM, VIC, Cy5 and ROX were chosen 
because the excitation and emission wavelengths are sufficiently different to allow 
accurate detection of each.  This reduces the risk of crosstalk, which is described in more 
detail in Sections 2.1.9.3.  All probes had black hole quenchers (BHQ) as quenchers with 
the exception of FHV and Tritrichomonas foetus which had minor groove binders (MGB).   
 
2.1.8 Laboratory methods 
2.1.8.1 Reconstitution of primers and probes 
Primers and probes were reconstituted according to the manufacturer’s instructions, in pH 
7 TE buffer (Ambion, Life Technologies, Paisley, UK) for all primers and Cy5 probes, and 
pH 8 TE buffer (Ambion, Life Technologies, Paisley UK) for all other probes.  The 
reagents were reconstituted to stock concentrations of 100µM for probes and 1000µM for 
primers. 
 
2.1.8.2 Sample panels used for multiplex assessment 
A strong positive control was used to manufacture a 10-fold dilution series to assess the 
multiplex assay over a range of Ct values, to determine the endpoint detection limit, and to 
assess the trace quality in comparison to single assays.  The positive control was a strongly 
positive clinical sample, an isolate or plasmid DNA.  The preparation of clinical samples 
used is described in section 2.1.8.3. 
 
To assess the specificity of the multiplex assays, pooled positive controls containing a 
range of human pathogens for human diagnostic assays was assessed, these controls 
included:- adenovirus; human herpes virus 6 and 7; parvovirus B19; Pneumocystis 
pneumonia; norovirus GI and GII; herpes simplex virus 2; varizella zoster virus Syphilis; 
Chlamydia trachomatis; cytomegalovirus; Epstein Barr virus; measles virus; rubella virus; 
astrovirus; rotavirus; sapovirus; influenza A, B, H1N1sw; H1N1sw(H275Y); coronaviruses 
229E, OC43, NL63 & HKU1; parainfluenza 1 to 4; rhinovirus; respiratory syncytial virus 
A and B; human metapneumovirus; and Mycoplasma pneumonia.  In addition, no-template 
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controls were tested.  No-template controls are negative controls which should contain no 
target nucleic acid, instead nuclease-free water is added to the PCR plate (plus mastermix) 
during set-up.  Large scale clinical validation will be required to fully validate these tests, 
however small panels (~20) of positive and negative clinical samples determined by “gold 
standards”, were tested where available.  At this stage, clinical samples have only been 
assessed for the feline respiratory, feline conjunctivitis, and GE 1 screens (FPV only).  
These panels assess the sensitivity and specificity of the assays.  
  
2.1.8.3 Sample preparation 
Clinical samples submitted to the GVDS laboratory for routine diagnostic testing were 
used in this study.  The type of sample assessed was dependent on the multiplex panel.  
Throat swabs were used for the respiratory panels, conjunctival swabs were used for the 
conjunctivitis panel, faecal samples were used for the gastroenteritis panel, blood samples 
collected into EDTA anticoagulant for the feline anaemia panel, and EDTA and gingival 
swabs were used for the feline gingivitis panel.  Swabs were placed into a tube containing 
lysis buffer (Buffer AL, Qiagen, Germany) which lyses the cells and preserves the 
DNA/RNA.  Blood samples were spun and separated; the serum or plasma was used for 
extraction.  Faecal samples required pre-extraction processing.  A small amount of faecal 
material was added to a cryovial and 1ml of lysis buffer was added.  The tube was then 
vortexed and left for 10 minutes at room temperature.  Then 200µl of the sample/lysis 
buffer mix was added to 1ml of lysis buffer and this was used for extraction. 
 
2.1.9 Optimisation of primer and probe concentrations 
As described in Chapter 1, the multiplex panels have been designed along syndromic lines 
offering users a single test to investigate clinical signs.  Each multiplex must be carefully 
optimised to ensure that multiplexing does not result in either a loss of sensitivity at the 
endpoint of detection or a loss in specificity as a result of crosstalk, cross reaction or 
competition in comparison to the single test.  The various stages involved in optimisation 
are outlined below. 
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2.1.9.1 Initial single assay probe and primer optimisation 
Prior to multiplexing the primers and probe of each assay were optimised as a single test.  
The optimal concentration of each primer and probe is when the trace quality is optimal 
and the Ct value is lowest (so most sensitive) (Gunson et al, 2008).  In order to determine 
the optimal primer concentrations a range of concentrations of the forward primer were run 
against a range of concentrations of the reverse primer in a primer chessboard (6.25 to 
100µM) (Gunson, Gillespie, and Carman, 2003).  These combinations of forward and 
reverse primers were tested with a positive control.  For the primer assessment, a probe 
concentration of 5µM is used.  Once the optimal primer concentrations were determined, a 
range of probe concentrations were assessed with the pre-determined primer optimal 
concentrations to determine the optimal probe concentration. 
 
2.1.9.2 Optimisation of the multiplexed assay  
The optimised single assays were then multiplexed together.  A 10-fold dilution series of a 
strong positive control was used to compare the multiplex to the single assays.  This was 
carried out to ensure that there is no loss in sensitivity at the endpoint of detection.  If a 
loss in endpoint detection was evident then this could be optimised through careful 
adjustment of the primer and/or probe concentrations.  If the issue cannot be rectified then 
the multiplex will not be developed further.  Following this, the traces were examined to 
ensure results are easily interpretable and ensure no cross-reaction or crosstalk was 
evident. 
 
2.1.9.3 Assess multiplex for crosstalk 
Crosstalk is caused by the fluorescence output from one dye ‘spilling over’ into another 
channel to create what appears to be two positive traces, one of which is false.  To 
eliminate crosstalk the probe concentrations need to be optimised, usually by reducing the 
concentration of the probe that is “spilling over” into the other channel.  This has to be 
done carefully to ensure that the probe concentration would not have a detrimental effect 
on the performance of that assay.  In order to do this several primer probe pools are made, 
each with a different concentration of the crosstalking probe (for example 10µM, 5µM, 
2.5µM).  These pools are then assessed with a 10-fold dilution series to determine if 
crosstalk is evident.  If reducing the concentration of the crosstalking probe does not 
completely eliminate the crosstalk, it may be necessary to increase the concentration of the 
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probe that is detected in the channel in which the crosstalking probe is spilling over.  In 
this way any crosstalk can be easily differentiated from a real trace. 
 
It is important to remember that for every change made to a probe concentration, the 
endpoint detection limit of that component needs to be re-assessed against the single assay 
to ensure that the re-optimisation does not result in a loss in sensitivity or specificity for 
any component in the multiplex. 
 
2.1.9.4 Assess multiplex for cross-reaction 
Cross-reaction of primers or probes within an assay, or the formation of primer-dimers, is a 
result of primers or probes hybridising to each other because of strings of complementary 
bases in the sequence.  When designing a new assay, primer design software helps to 
reduce these issues.  Cross-reaction can inhibit or reduce the sensitivity of a reaction by 
using up the available reagents, it can also cause non-specific amplification traces if a 
probe were to cross-react with a primer.  To assess if such a problem exists in a multiplex, 
no-template controls (water) can be run through the multiplex.  If cross-reaction is 
occurring you would expect to see false positive/non-specific traces in these wells.  To 
determine if cross-reaction is reducing the performance of the assays, the multiplex assay 
should be compared to the single assays.  Cross-reaction can be eliminated with careful 
optimisation, by determining which components are cross-reacting and optimising the 
concentration of these components.  This can be assessed by carrying out a ‘plus/minus’ 
experiment, where the multiplex assay is made up, minus one assay, e.g. 
FHV/FCV/B.bronchiseptica no IC; FHV/FCV/IC no B.bronchiseptica and so on to 
determine which part is causing the false positives or reduction in performance.  Once the 
assay causing the issues is determined, a further plus/minus experiment is carried out 
removing each primer and probe of that assay to determine which primer or probes are 
cross-reacting.  Reducing the concentration of one or both of these components may then 
eliminate cross-reaction.  As with optimising crosstalk, the endpoint detection limit of that 
component needs to be re-assessed against the single assay to ensure that the re-
optimisation does not result in a loss in sensitivity or specificity for any component in the 
multiplex. 
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2.1.9.5 Assess multiplex for competition 
Multiplexing can create competition between targets where a stronger positive out-
competes a weaker positive by using up available reagents, resulting in a false negative 
result for the out-competed target.  Therefore it is important to ensure that mixed infections 
are detected effectively, and also to ensure that the internal control is not out-competed 
leading to a false inhibited results, or indeed that the internal control does not out-compete 
a genuine positive, resulting in a false negative result.   
 
To assess if there was any competition between the internal control and any target within 
the multiplex, a 10-fold dilution series of each target was compared with and without IC in 
the sample and tested in duplicate.   
 
Where mixed infections are expected, panels of simulated samples were generated using 
eight dilutions manufactured from a strong positive control to assess if any competition 
existed between the targets in a multiplex.  For example, one panel contained various 
concentrations of FCoV and Salmonella, one contained FCoV and C.jejuni and a third 
contained Salmonella and C.jejuni.  The dilution series from which these panels was made 
were tested in duplicate using the multiplex and singleplex assays to assess if the multiplex 
missed any positives due to competition that would be detected by a singleplex assay.  
Mixed infections are likely in respiratory samples and gastroenteritis samples.  Mixed 
infections were assessed for the gastroenteritis multiplexes, but have not yet been 
investigated for the respiratory multiplex as work was focused on improving the FCV 
assay in the timescale of the study.   
 
2.1.10 Evaluation of the endpoint sensitivity of the multiplex in comparison 
to the single assays  
The endpoint sensitivity of the optimised multiplex was compared to the optimised single 
assay by using a 10-fold dilution series of a strong positive control for each target.  The 
dilution series was tested in duplicate through the single and multiplex assays on at least 
four PCR runs. 
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2.1.11 Inter-assay and intra-assay variability 
The inter-assay and intra-assay variability of the multiplex should be assessed to determine 
the robustness of the multiplex assay.  The intra-assay (repeatability) variability was 
assessed by testing a positive control in 20 wells on one PCR run.  The inter-assay 
variability (reproducibility) was not assessed in the timescale of this study. To assess the 
inter-assay variability positive run controls are monitored controls over approximately 20 
PCR runs.  These experiments assess how well the assay performs over time, on different 
ABI instruments and with different users to assess the whole system reproducibility of the 
multiplex.  The co-efficient of variation (CoV) for the intra-assay variability was 
calculated for each assay, this is the standard deviation divided by the mean Ct value of the 
positive controls tested, and so shows the extent of variation in relation to the mean of the 
controls.  A low CoV value indicates low variation which suggests good inter-assay and 
intra-assay variability, suggesting that the assay is repeatable and reproducible and 
therefore robust. 
 
2.1.12. Evaluation of the sensitivity and specificity of the multiplex 
Ideally, clinical validation comparing the multiplex assay to a “gold standard” for each 
pathogen should be carried out.  This can be a large scale prospective evaluation where the 
multiplex assays are run in parallel to a gold standard and the results compared, or 
retrospectively testing a panel of positive and negative samples previously assessed by a 
gold standard.  This gives the clinical sensitivity and specificity of the multiplex, and if 
planned properly can determine the negative and positive predictive values with prevalence 
data.  Care must be taken when comparing PCR to a “gold standard” as PCR is often more 
sensitive than traditional methods, therefore if PCR is compared to a gold standard that is 
of poor sensitivity, the specificity of the PCR may falsely appear to be poor, as the PCR 
will detect more positives than the “gold standard” method.  Therefore the quality of the 
“gold standard” should be taken into account when determining clinical sensitivity and 
specificity.  It should be noted that completing the clinical validation of the feline and 
canine multiplex assays was beyond the timescale of this research project, however 
preparations to carry out the validations have been made.  Small panels of known positive 
and negative clinical samples have however been assessed using the multiplex assays for 
FHV, FCV, B.bronchiseptica, M.felis, C.felis, FPV and CPV, which gives a limited 
comparison to the gold standard methods.   
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2.2 Methods specific to each multiplex 
2.2.1 Feline respiratory multiplex  
The feline respiratory panel consists of FHV, FCV, B.bronchiseptica and an IC (mumps 
virus).  FHV was labelled with a FAM dye, FCV with a HEX dye, B.bronchiseptica with a 
Cy5 dye, and the IC was labelled with ROX.  Primers and probes were optimised as 
described in Section 2.1.8. 
 
2.2.1.1 Clinical samples  
The performance of the multiplex assays was assessed using a panel of known positive and 
negative clinical samples for each pathogen; for the feline respiratory panel throat swabs 
were tested.  The FHV samples tested were previously detected as positive by a singleplex 
FHV real time PCR and virus isolation, and the FCV and B.bronchiseptica samples were 
previously determined positive by virus isolation and bacterial culture respectively.  Eleven 
known FHV-positive, initially 10 known FCV-positive, and 10 known B.bronchiseptica-
positive throat swabs were tested through the multiplex.  In addition, 15 throats swabs 
known to be negative for all three pathogens were tested.  Testing this retrospective sample 
panel gives a limited comparison to the gold standard and assesses specificity, by ensuring 
each positive sample is correctly detected by the relevant component of the multiplex, but 
not by the other components of the multiplex.  Not all FCV positive clinical samples were 
detected by the multiplex therefore to further investigate the sensitivity of the FCV PCR, 
an additional 27 known positive clinical samples were tested, along with typed FCV 
isolates (FCV virus isolate(VI)1, FCV VI2, FCV VI3) and 13 un-typed field isolates from 
around the UK. 
 
2.2.2 Subsequent Methods following unexpected FCV PCR assay results 
The initial PCR results obtained for the FCV clinical samples suggested that the FCV PCR 
was insensitive, which led to further sample panels being tested.  Further assessment was 
also carried out by using a two-step RT-PCR kit designed for use with multiplex assays, by 
further concentrating the nucleic acid extract, and by assessing other extraction platforms 
available in the laboratory.  Alternative FCV assays published in the literature were also 
assessed, and furthermore an in-house FCV real-time PCR assay was designed and 
assessed to see if sensitivity could be improved. 
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2.2.2.1 Assessment of FCV PCR with a two-step RT-PCR kit 
A two-step RT-PCR kit was assessed:- the Quanta qScript cDNA kit/Quanta multiplex 
qPCR supermix.  To assess if the PCR kit improved sensitivity, five virus isolation positive 
samples found to be negative by the multiplex assay previously were tested using this kit. 
Studies have suggested that two-step RT-PCR protocols are more sensitive than one-step 
due to secondary structures in RNA.   
The cDNA mastermix for each sample consists of the following: 4.95µl of qScript reaction 
mix plus was added to 1.2375µl qScript reverse transcriptase.  5.625µl of cDNA 
mastermix was then added to 16.875µl of extracted RNA.  The RT step was carried out on 
an ABI 9700 PCR machine using the following parameters: 22ºC for 5 minutes, 42ºC for 
30 minutes and 85ºC for 5 minutes.   
For PCR 5.5µl of the primer probe pool was added to 27.5µl of 2x Quanta qPCR 
mastermix, PCR was then carried out on the ABI 7500 with the following parameters: 2 
minutes at 50°C, 95ºC for 2 minutes, followed by 40 cycles of 95ºC for 8 seconds and 
60ºC for 34 seconds. 
 
2.2.2.2 Concentration of the nucleic acid extraction and evaluation of other 
extraction platforms 
The extraction of FCV-positive clinical samples on the easyMag was assessed.  
Concentrating the nucleic acid may improve sensitivity by increasing the amount of RNA 
in the extract.  Several extraction and elution volumes were compared raging from a 1.81 
times concentration (current) to a 40 times concentration.  Other available automated 
extraction platforms available were also assessed (Qiagen MDx, Abbot M2000).  The 
standard viral protocol for each of these platforms was used followed as per 
manufacturer’s instructions.   
 
2.2.2.3 Alternative published assays 
The literature was searched for alternative FCV assays to assess if an alternative assay may 
be more sensitive that the assay original used in the multiplex, published by Abd-Eldain et 
al (2009).  Two further assays were found (Helps et al, 2005; Chander et al, 2007) and 
assessed.  All three assays are shown in Table 2.3; two assays (Abd-Eldain et al, 2009; 
Helps et al, 2005) target different areas of ORF1, one assay targets ORF2 (Chander et al, 
2007).  
 51 
 
2.2.2.4 Design of an in-house FCV assay 
FCV is a member of the same family as norovirus and sapovirus, and studies on these 
viruses have found the open reading frame (ORF)1/2 breakpoint region to be a conserved 
region of the genome (Kageyama et al 2003, Chan et al 2005), therefore based on these 
previous findings we designed an assay that targets this breakpoint region. 
 
Fifteen FCV strains sequenced at the ORF1/ORF2 region were found on BLAST, and a 
small conserved region was identified (Figure 2.4).  A conserved sequence of 163 bases 
(5229-5391) was used for Primer-Express analysis, and 50 possible combinations of 
primers and probes were found.  These primers and probes were aligned against the 15 
sequences on BLAST and the primers and probe with the best match were selected.  The 
forward primer contained the most mis-matches therefore three different sets of forward 
primer were ordered and assessed (Table 2.4).  This assay was assessed using the panel of 
typed and un-typed isolates. 
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Table 2.3 Feline calicivirus TaqMan assays assessed in this study 
Assay Target  5’-3’ sequence 
Abd-Eldaim et al (2009) 
 
 
OFR1 0-120 Forward primer GTA AAA GAA ATT TGA GAC AAT 
Reverse primer TAC TGA AGW TCG CGY CT 
Probe CAA ACT CTG AGC TTC GTG CTT AAA 
Helps et al  (2005) 
 
 
ORF1 2410-2540 Forward primer GTT GGA TGA ACT ACC CGC CAA TC 
Reverse primer CAT ATG CGG CTC TGA TTT GGC CTG  
Probe TCG GTG TTG ATT TGG CCT G 
Chander et al (2007) 
 
 
Capsid protein gene 5320-5470 Forward primer CAA CCT GCG CTA ACG 
Reverse primer TCC CAC ACA GTT CCA AAT T 
Probe CTT AAA TAY TAT GAT TGG GAY CCC CA 
In-house 
 
 
ORF1/2 BP junction 5245-5335 Forward primer RCG CGG WBY GAH CAK A* 
Reverse primer ATG TGC TCA ACC TGC GCT AA 
Probe MCG MYC THC ACT GYG ATG TKT TCR AA 
*see table 2.4 also 
5
2
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Table 2.4 In-house designed feline calicivirus assay: possible forward primer 
combinations 
1 primer covering all mismatches 
RCG CGG WBY GAH CAK A 
  
(a) 1 primer covering majority, 2 degenerate primers covering rest 
F1a: GCG CGG TCC GAT CAG A 
F2a: GCG CGG WCY GAY CAG A 
F3a: RCG CGG TBY GAW CAK A 
 
(b) 8 primers covering all strains 
F1b: GCG CGG TCC GAT CAG A 
F2b: GCG CGG TCT GAC CAG A 
F3b: GCG CGG ACT GAC CAG A 
F4b: GCG CGG TTC GAT CAG A 
F5b: ACG CGG TCT GAT CAG A 
F6b: GCG CGG TGC GAT CAG A 
F7b: GCG CGG TCT GAA CAT A 
F8b: GCG CGG TCC GAC CAG A 
The green letters highlight where degenerate bases have been added, these represent a position in the sequence that can have multiple 
possible bases
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Figure 2.4 Conserved region of the feline calicivirus genome 
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2.2.3 Feline conjunctivitis multiplex  
The feline conjunctivitis panel consists of FHV, C.felis, M.felis and an IC (HSV-1).  FHV 
was labelled with a FAM dye, M.felis with a HEX dye, C.felis with a Cy5 dye, and the IC 
(HSV-1) was labelled with ROX. Primers and probes were optimised as described in 
Section 2.1.8. 
 
2.2.3.1 Clinical samples  
The performance of the multiplex assays was assessed using a panel of known positive and 
negative clinical samples for each pathogen; for the feline conjunctivitis panel eye swabs 
were tested.  Eleven known FHV-positive (by real-time PCR and virus isolation) 13 known 
C.felis positive (by PCR), and 12 known M.felis positive (by real-time PCR and bacterial 
culture) eye swabs were tested through the multiplex.  In addition 15 eye swabs known to 
be negative for all three pathogens were tested.  Testing this retrospective sample panel 
gives a limited comparison to the gold standard and specificity, by ensuring each positive 
sample is correctly detected by the relevant component of the multiplex, but not by the 
other components of the multiplex. 
 
2.2.4 Feline anaemia panel  
The feline anaemia panel consists of two multiplex assays, Anaemia 1 (An1) and Anaemia 
2 (An2).  The An1 multiplex consists of FeLV which was labelled with a FAM dye, FIV 
which was labelled with a HEX dye, and FCoV which was labelled with a ROX dye.  
Primers and probes were optimised as described in Section 2.1.8.1.  Anaemia 2 consists of 
the feline haemoplasmas (Mhf, CMt and CMhm) and an IC (mumps virus).  The An2 assay 
was unable to be assessed as positive control material could not be obtained for the three 
haemoplasmas in the timescale of the project. 
 
2.2.5 Feline gingivitis multiplex  
The feline gingivitis multiplex consists of FeLV which was labelled with a FAM dye, FIV 
which was labelled with a HEX dye, FCV which was labelled with a Cy5 dye, and an IC 
(mumps virus) labelled with a ROX dye.  Primers and probes were optimised as described 
in Section 2.1.8. 
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2.2.6 Feline and canine gastroenteritis panel 
The feline and canine gastroenteritis panel consists of four multiplex assays, GE1 consists 
for FPV/CPV labelled with a FAM dye and an IC labelled with a ROX dye, GE2 consists 
of FCoV/CCoV labelled with a FAM dye, Salmonella labelled with a HEX dye and 
C.jejuni labelled with a Cy5 dye, GE3 consists of Giardia labelled with ROX, T.foetus 
labelled with HEX, and C.parvum labelled with Cy5, and GE 4 (for canine only) consisting 
of E.coli toxin ST1, C.difficile toxins A and B and C.perfringens toxin CPE.  It was not 
possible to source an assay that specifically detected both C.difficile toxins A and B, during 
the timescale of the study on a specific toxin B assay could be sourced.  Primers and 
probes were optimised as described in Section 2.1.8.  The GE4 assays was initially 
assessed with positive controls, however the controls were not detected, suggesting that the 
assays may not be sensitive or specific for the toxins.  This assay was not able to be further 
assessed in the timescale of this project. 
 
2.2.6.1 Clinical samples  
The performance of the GE1 multiplex assay was assessed using a panel of known positive 
and negative clinical samples for each pathogen, to date only FPV positive and negative 
clinical samples (faecal samples) have been assessed, these samples had been tested by 
traditional gel based PCR.  Fourteen known positive faecal samples and 28 known negative 
faecal samples were assessed.  Testing this retrospective sample panel gives a limited 
comparison to the gold standard and specificity, by ensuring each positive sample is 
correctly detected by the relevant component of the multiplex, but not by the other 
components of the multiplex. 
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CHAPTER 3 
3. Results 
This chapter outlines the results of the optimisation of each multiplex.  Following this, the 
results of the evaluation of each multiplex are presented, which includes the endpoint 
detection limit of each multiplex in comparison to the single assays, the intra-assay 
variability of each multiplex, and if carried out the sensitivity and specificity of each 
multiplex with a small panel of clinical samples.  Not all stages of the multiplex evaluation 
were completed for all multiplexes in the timescale of the project. 
 
3.1 Feline respiratory multiplex 
3.1.1 Initial single assay primer probe optimisation 
The FHV, FCV and B.bronchiseptica assays were optimised first as single assays.  Each 
primer and probe set was individually optimised and the final concentrations are given in 
Table 3.1. 
 
3.1.2 Multiplex primer probe optimisation 
The single assays were then multiplexed together; a 10-fold dilution series of a strong 
positive control and “no template” controls (water) were used to assess the performance 
and trace quality of the multiplex in comparison to the single assays.  At this stage any 
signs of crosstalk, cross-reaction and competition were investigated.  The results are 
described below.  
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Table 3.1 Optimal probe concentrations (µM) 
Multiplex Screen Optimal concentration (µM) 
Single   Multiplex 
Feline respiratory Feline herpes virus 5 0.5 
Feline calicivirus 10 10 
 Bordetella bronchiseptica 5 0.5 
Internal control 5 5 
Feline 
conjunctivitis 
Feline herpes virus 5 2.5 
Chlamydophila felis 20 30 
Mycoplasma felis 20 20 
Internal control 5 5 
Feline Anaemia 1 Feline leukaemia virus 10 - 
Feline immunodeficiency virus 30 - 
Feline coronavirus 10 - 
Feline Gingivitis  Feline leukaemia virus 10 - 
Feline immunodeficiency virus 30 - 
Feline calicivirus 10 - 
Internal control 10 - 
GE 1 Parvovirus 10 10 
Internal control 10 10 
GE 2 Salmonella 10 10 
Campylobacter jejuni 25 25 
Coronavirus 10 10 
GE 3 Cryptosporidium .parvum 10 10 
Giardia 10 10 
Tritrochomonas foetus 10 10 
The primers and probes of each assay was optimised as a single assay and, if necessary, within the multiplex assay. GE: gastroenteritis 
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3.1.2.1 Crosstalk 
On initial assessment of the multiplex, crosstalk from the FAM (FHV) channel into HEX 
(FCV) was evident.  Several concentrations of the FHV probe were assessed, and it was 
found that reducing the FHV probe concentration to 0.5µM eliminated the crosstalk.  The 
endpoint sensitivity of each assay in the multiplex was not affected by the re-optimisation 
of the FHV and FCV probes.   
 
3.1.2.2 Cross-reaction 
Evidence of cross-reaction was seen in the “no template” control wells, resulting in false 
positive B.bronchiseptica traces.  A ‘plus/minus’ experiment was carried out and the 
results suggested that the B.bronchiseptica probe was cross-reacting with more than one 
component in the multiplex (Figure 3.1).  Several concentrations of the B.bronchiseptica 
probe were assessed in the multiplex and it was found that by reducing the 
B.bronchiseptica probe concentration to 0.5µM the cross-reaction was eliminated without 
any detrimental effect on the B.bronchiseptica sensitivity (Figure 3.2). 
 
3.1.2.3 Competition 
Since an IC is included in the multiplex, the possibility of competition was studied.  A 
dilution series of each target with and without the IC in the samples was compared.  For 
FHV, when the IC was excluded, the assay detected the target down to a dilution of 10
-6
, 
when the IC was included the assay detected the target down to 10
-7
.  For FCV, the assay 
detected the target down to a dilution of 10
-6
 both with and without the IC.  Similarly for 
B.bronchiseptica, the endpoint detection limit was 10
-7
 with and without the IC (Table 
3.2).  The Ct values of the IC were consistently around 25 (the exact values for each 
dilution are given in Table 3.2).  These results suggest that no significant competition was 
evident.  The final optimised concentrations of the respiratory multiplex are given in Table 
3.1.  The assessment of mixed respiratory infections has not yet been investigated. 
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Figure 3.1  Cross-reaction observed in the respiratory multiplex. 
A 
Minus IC assay    Minus B.bronchiseptica assay 
  
 
Minus FCV assay   Minus FHV assay 
  
B 
Multiplex    Minus B.bronchiseptica forward primer 
  
 
Minus B.bronchiseptica reverse primer Minus B.bronchiseptica probe 
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Figure 3.2 Elimination of Bordetella bronchiseptica probe cross-reaction. 
A  
 
B   
    
C  
 
B.bronchiseptica 
Positive Control 
No cross-reaction 
B.bronchiseptica 
Positive Control 
 
B.bronchiseptica 
Positive Control 
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Table 3.2 Competition of each target with internal control in the respiratory screen  
Dilution Feline herpesvirus Feline calicivirus  Bordetella bronchiseptica 
No IC With IC No IC With IC No IC With IC 
10
-1
 21.55 21.27 25.29 19.57 17.25 25.14 19.03 19.12 25.33 
10
-2
 24.97 24.40 25.37 23.70 21.00 25.26 22.75 22.26 25.00 
10
-3
 28.32 27.45 25.16 27.58 24.41 25.32 24.85 25.15 25.22 
10
-4
 31.27 30.29 25.16 30.66 28.33 25.40 28.05 28.22 25.35 
10
-5
 35.19 32.74 25.19 34.51 32.26 25.24 31.17 30.79 25.23 
10
-6
 N 36.50 25.23 N N 25.07 34.97 32.78 25.32 
10
-7
 N 37.77 25.28 N NT NT N NT NT 
A 10-fold dilution series of each pathogen was assessed with and without an internal control in the sample to assess if there was any 
competition between the internal control and the target pathogens.  N: Negative; NT: Not tested; IC: internal control.  IC Ct given in 
faded text under “with IC” column 
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3.1.3 Evaluation of the endpoint sensitivity of the multiplex in comparison to 
the single assays 
The endpoint sensitivity of the multiplex was assessed in comparison to the single assays.  
In order to do this the endpoint detection limit of each multiplex component was compared 
to that of the single assays using a 10-fold dilution series of a positive control.  Testing was 
done in duplicate wells.  When testing the dilution series of FHV the single assay detected 
the 10
-8
 dilution in one out of two wells, whereas the multiplex detected the target down to 
10
-8
 in both wells.  For FCV the single test detected the 10
-8
 dilution in both wells, and the 
multiplex detected down to 10
-8
 in one out of two wells.  When testing the dilution series 
of B.bronchiseptica the single assay detected down to the 10
-5
 dilution in one out of two 
wells, whereas the multiplex detected down to 10
-5
 in both wells (Table 3.3).  In addition, 
due to the variability of FCV, three typed FCV isolates (FCV VI1, VI2, VI3) and 13 un-
typed field isolates were assessed at the endpoint detection.  For all samples, similar 
endpoints were found between single and multiplex assays (data not shown).  These results 
suggest that the endpoint sensitivity of the multiplex assay is comparable to that of the 
single assays. 
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Table 3.3 Endpoint detection limit of the respiratory multiplex in comparison to the 
single assay 
Dilution Feline herpesvirus Feline calicivirus  Bordetella bronchiseptica 
Single Multiplex Single Multiplex Single Multiplex 
10
-1
 16.06 15.32 13.90 14.38 26.09 24.86 
10
-2
 19.29 18.49 17.61 17.70 29.09 28.19 
10
-3
 21.99 21.65 20.83 21.32 32.02 32.21 
10
-4
 25.31 24.69 24.95 24.82 35.72 34.06 
10
-5
 28.39 27.91 28.82 28.94 37.30/N 36.93 
10
-6
 29.36 31.58 32.35 32.92 N N 
10
-7
 33.57 34.73 37.39 36.77 N N 
10
-8
 35.66/N 37.07 39.58 38.70/N N N 
10
-9
 N N N N NT NT 
10
-10
 N N N N NT NT 
A 10-fold dilution series of each pathogen was assessed using a single assay for each pathogen and the multiplex assay.  N: negative; 
NT: not tested 
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3.1.4 Intra-assay variability 
The intra-assay variability was assessed and the co-efficient of variation (CoV) values are 
shown in Table 3.4.  The CoV values were low for each component; FHV CoV 0.003, 
FCV CoV 0.004 and B.bronchiseptica CoV 0.006.  The results suggest that the intra-assay 
variability of the assay i.e. precision, is good for each component as little variation was 
observed when the positive control was repeatedly tested.  The assessment of the inter-
assay variability of the assay is ongoing. 
 
3.1.5 Evaluation of the sensitivity and specificity of the multiplex 
The multiplex was evaluated using a small panel of known positive and negative clinical 
samples.  The FHV component of the assay detected successfully the 11 samples that 
contained FHV.  The B.bronchiseptica component of the assay correctly detected the 10 
B.bronchiseptica positive samples present in the panel.  No false positives were detected in 
the 15 known negative samples and no cross-reaction was observed for FHV and 
B.bronchiseptica. 
 
For FCV on initial screening not all of the 10 known positive throat swab samples were 
detected by the single and multiplex assays.  One clinical sample that was highly positive 
for FHV (Ct 16) was false negative for FCV in the multiplex but positive in the single test.  
This sample was consistently positive in the FCV single test (Ct ~22) and negative in the 
multiplex, therefore the false negative result for FCV is likely due to competition, i.e. the 
strong FHV sample out-competed the weaker FCV sample resulting in a false negative 
result for the FCV sample.  The other false negative samples were not mixed infections.  
Therefore an additional panel of FCV positive samples was assessed.  The panel was 
assessed using the respiratory multiplex assay and the single FCV assay.  Eight out of 24 
of the additional clinical samples were negative on initial screening.  The false negative 
samples were repeated in triplicate and gave plus/minus results (i.e. 1/3 or 2/3 wells 
negative) for all but two samples, which were consistently negative.  In addition the mean 
Ct value of the clinical samples was 31.71 by the multiplex (29.84 by single assay).  FCV 
is detected traditionally by virus isolation; therefore PCR would be expected to detect FCV 
in clinical samples at low Ct values (strong positives).  The results suggest that the single 
and multiplex are comparable and that the loss in sensitivity is not a result of multiplexing.  
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The FCV component of the respiratory screen was further investigated and is detailed 
below in section 3.2. 
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Table 3.4 Intra-assay variability  
Multiplex Target Mean (20) CoV 
Feline 
Respiratory 
Feline herpesvirus 29.35 0.003 
Feline calicivirus 27.99 0.004 
Bordetella bronchiseptica 28.01 0.006 
Feline 
Conjunctivitis  
Feline herpesvirus 29.93 0.007 
Myoplasma felis 27.90 0.004 
Chlamydophila felis 28.64 0.006 
GE1 Parvovirus 27.41 0.009 
GE2 Coronavirus 26.91 0.005 
Salmonella 24.42 0.004 
Campylobacter jejuni 26.39 0.005 
GE3 Tritrichomonas foetus 26.93 0.013 
Giardia 30.48 0.008 
Cryptosporidium parvum 28.07 0.003 
The intra-assay variability is presented as a co-efficient of variation (CoV) value, a low value indicates low variability and so good 
repeatability for the assay.  GE: gastroenteritis   
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3.2 Feline calicivirus further results  
3.2.1 Assessment of FCV PCR with a two step RT-PCR kit 
A two-step RT-PCR was assessed to determine if sensitivity could be improved.  The 
results suggest that using a two step RT-PCR kit may improve the sensitivity of the FCV 
PCR marginally as the Ct was lower (stronger), however no significant improvement was 
seen at the endpoint of detection (Table 3.5).  These results suggest that the loss in 
sensitivity is not RT-PCR kit related. 
 
3.2.2 Concentration of the nucleic acid extraction and evaluation of other 
extraction platforms 
The result of assessing different nucleic acid concentrations suggested that increasing the 
concentration of the sample five-fold at extraction improves the sensitivity 10-fold (by 1 
log) therefore adjusting the elution volume of respiratory samples may improve the 
sensitivity of the FCV assay (Table 3.6).  Other automated extraction platforms available 
were also assessed (Qiagen MDx, Abbot M2000) and results were similar to the original 
easyMag results (data not shown). 
 
3.2.3 Alternative published assays 
The three alternative assays were assessed using the panel of 24 culture-positive clinical 
samples (Table 3.7) and 15 isolates (Table 3.8).  The Abd-Eldaim assay detected 14 out of 
the 24 samples as positive, the Chander assay detected 18 samples positive, and the Helps 
assay detected 23 samples positive (Table 3.7).  Four samples were false negative in both 
the Abd-Eldaim and Chander assays, however the other false negatives, and the one false 
positive by the Helps assay were not identical across the three assays. 
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Table 3.5 Comparison of a one and two step RT-PCR kit for Feline calicivirus 
FCV One-step Ambion Two-step Quanta 
FCV1 33.07 33.70 
FCV2 32.02 34.85 
FCV3 N 37.17 
FCV4 31.63 31.51 
FCV15 N 37.98 
FCV VI1 10-1 12.95 14.33 
10-2 16.74 17.76 
10-3 20.73 20.70 
10-4 24.04 24.24 
10-5 26.97 27.42 
10-6 NT NT 
10-7 34.71 33.97 
10-8 36.91 N 
FCV VI2 10-1 16.12 13.58 
10-2 20.38 16.96 
10-3 23.63 20.40 
10-4 27.41 23.26 
10-5 30.71 27.39 
10-6 34.45 30.69 
10-7 36.69/N 34.24 
10-8 N 38.69 
FCV VI3 10-1 15.63 17.42 
10-2 20.33 21.97 
10-3 24.86 25.39 
10-4 29.08 29.34 
10-5 33.04 33.31 
10-6 36.68 37.31 
10-7 N N 
10-8 N 39.93/N 
A panel of feline calicivirus (FCV) samples were tested using a one and two step RT-PCR kit (multiplex kit) and the results compared.  
N: negative; NT: not tested 
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Of note there were several significant differences in Ct values between the FCV assays, for 
example sample FCV6 was negative by the Abd-Eldaim assay and positive by the other 
assays, however there was an 8 Ct difference between the Chander assay (Ct 19.89) and 
Helps assay (Ct 28.09).  Similarly sample FCV23 was negative by the Abd-Eldaim assay 
and positive by the other assays; however this time the Chander assay had a higher Ct 
value (Ct 37.71) than the Helps assay (Ct 25.60).  There was no pattern where for example 
one test consistently detected samples at a higher Ct than the other tests; the results were 
variable from sample to sample suggesting that the assays may detect some strains better 
than others.  Overall the Helps assay performed the best on this panel of samples. 
 
On assessment of the isolate panel the Abd-Eldaim and Helps assays detected all the 
isolates in the panel, whereas the Chander assay failed to detect two of the un-typed 
isolates (Table 3.8). 
 
An interesting observation was that the Chander assay produced different types of 
exponential curve (Figure 3.3).  The majority of positive traces were of a similar type of 
curve; however three clinical samples and three isolates, one the typed FCV VI3, had a 
noticeably different type of curve.   
 
3.2.4 Comparison of the in-house FCV assay to other published assays 
The in-house assay was compared to the other FCV assays using the 13 isolates from 
around the UK and the three typed isolates (Table 3.8).  The assay was significantly less 
sensitive than the other assays, detecting all isolates at high Ct values (weakly positive) 
and therefore the in-house assay not assessed further.   
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Table 3.6 Concentration of feline calicivirus nucleic acid elute on easyMag 
Concentration FCV Ct 
x 40 25.67 
x 20 26.03 
x 10 26.60 
x 5 26.34 
x 2 29.14 
Standard (x 1.81) 29.40 
A feline calicivirus (FCV) positive sample was concentrated to various degrees on the easyMag and the results compared.  Ct: cycle 
threshold; x: times concentrated 
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Table 3.7 Comparison of the two alternative published feline calicivirus assays to the 
original selected published assay (Abd-Eldaim et al, 2009)  
Clinical samples 
(24) 
Abd-Eldaim Chander Helps 
FCV1 N 37.28 36.61 
FCV2 N N 34.59 
FCV3 N 36.65 34.00 
FCV4 N N 31.09 
FCV5 29.08 26.31* 23.83 
FCV6 N 19.89 28.09 
FCV7 25.23 N 20.34 
FCV8 25.81 24.99 27.17 
FCV9 20.38 25.56 27.49 
FCV10 25.09 24.48 22.10 
FCV11 29.80 22.92 22.60 
FCV12 27.51 25.18 N 
FCV13 25.18 22.57 38.04 
FCV14 29.48 20.19* 24.78 
FCV15 N 26.04 29.85 
FCV16 28.91 35.41 23.19 
FCV17 N N 34.04 
FCV18 21.72 N 21.20 
FCV19 23.65 19.05 22.01 
FCV20 29.16 28.64* 30.86 
FCV21 N N 28.65 
FCV22 25.01 24.12 30.32 
FCV23 N 37.71 25.60 
FCV24 N 23.15 26.25 
The feline calicivirus (FCV) assay originally chosen and assessed with the multiplex was the Abd-Eldaim et al (2009) assay.  In the 
literature two alternative assays are published (Chander et al (2007) and Helps et al (2005)), these assays were assessed alongside the 
Abd-Eldaim et al (2009) assay with a panel of FCV positive samples and isolates.  N: negative; * strange traces 
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Table 3.8 Comparison of the in-house designed feline calicivirus assay to the 
published assays 
Isolates (15) Abd-Eldaim Chander Helps In-house 
FCV VI untyped 1 13.91 N 15.22 26.20 
FCV VI untyped 2 23.38 17.44* 15.81 29.34 
FCV VI untyped 3 29.32 20.70 14.99 27.39 
FCV VI untyped 4 15.99 13.25 13.37 25.51 
FCV VI untyped 5 14.64 13.18 12.17 27.54 
FCV VI untyped 6 19.40 15.42* 13.71 29.83 
FCV VI untyped 7 11.67 18.77 11.29 29.92 
FCV VI untyped 8 14.20 13.13 17.99 25.33 
FCV VI untyped 9 17.25 N 15.11 28.89 
FCV VI untyped 10 18.38 17.81* 20.13 34.52 
FCV VI untyped 11 14.19 11.36 NT 27.21 
FCV VI untyped 12 15.05 28.83 15.59 31.50 
FCV VI1 10.22 10.53 9.43 25.19 
FCV VI2 10.96 7.41 7.80 24.71 
FCV VI3 13.47 11.28* 12.63 25.45 
The three published assays were then compared to an assay designed in-house using a panel of positive FCV isolates.  N: negative; FCV 
VI: feline calicivirus virus isolate; *strange traces 
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Figure 3.3 Strange curves observed with the Chander et al (2007) assay. 
 
 
   
B 
A 
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3.3 Feline conjunctivitis multiplex 
3.3.1 Initial single assay primer probe optimisation 
The FHV, C.felis and M.felis assays were optimised as single assays.  Each primer and 
probe was individually optimised, the optimal concentrations are given in Table 3.1. 
 
3.3.2 Multiplex primer probe optimisation 
The optimised assays were then multiplexed together and a 10-fold dilution series of a 
strong positive control was used to assess the performance of the multiplex in comparison 
to the single assays.  At this stage any signs of crosstalk, cross-reaction and competition 
were investigated.  The results are detailed below.  
 
3.3.2.1 Crosstalk 
On initial assessment, cross-talk from the FAM (FHV) channel into HEX (M.felis) was 
evident.  Several concentrations of the FAM probe was assessed, it was found that 
reducing the probe concentration to 2.5µM significantly reduced the crosstalk.  To 
eliminate the crosstalk, the HEX probe concentration was boosted to 30µM.  The 
sensitivity of the FHV and M.felis components of the multiplex were not affected by 
changing the probe concentration. 
 
3.3.2.2 Cross-reaction 
No cross-reaction was evident in this multiplex pool  
 
3.3.2.3 Competition 
Since an IC is included in the multiplex, the possibility of competition was studied.  A 
dilution series of each target, with and without the IC, was compared.  For FHV the assay 
detected the target down to a dilution of 10
-7
 both with and without the IC.  For M.felis the 
assay detected down to 10
-7 
when no IC was present and 10
-6
 with IC.  Similarly for C.felis 
the endpoint detection limit was 10
-7
 without IC and 10
-8
 with IC (Table A-1).  The Ct 
values of the IC are given in Table A-1.  These results show that no significant competition 
was evident.  The assessment of competition in mixed infections is yet to be carried out.  
The final optimised concentrations of the respiratory multiplex are given in Table 3.1. 
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3.3.3 Evaluation of the endpoint sensitivity of the multiplex in comparison to 
the single assays 
The endpoint detection limit of each component of the multiplex was compared to the 
single assays using a 10-fold dilution series of a positive control tested in duplicate wells.  
When testing the dilution series of FHV the multiplex assay detected the 10
-6
 dilution in 
one out of two wells, the single test detected down to 10
-6
 in both wells.  For M.felis, both 
assays detected down to the 10
-9
 dilution one out of two wells.  When testing the dilution 
series of C.felis the single and multiplex assays both detected down to the 10
-6
 (Table A-2).  
These results suggest that the endpoint detection limit of the multiplex assay is comparable 
to that of the single assays.   
 
3.3.4 Intra-assay variability 
The intra-assay variability was assessed and the CoV values are given in Table 3.4.  The 
CoV values were low for each component; FHV CoV 0.007, M.felis CoV 0.004 and C.felis 
CoV 0.006.  The results suggest that the repeatability of the assay is good for each 
component as little variation was observed.  The inter-assay variability assessment is 
ongoing. 
 
3.3.5 Evaluation of the clinical sensitivity and specificity of the multiplex 
The multiplex was evaluated using a small panel of known positive and negative clinical 
samples.  The FHV component of the assay detected successfully the 11 samples that 
contained FHV.  The M.felis component of the assay correctly detected the 12 M.felis 
positive samples present in the panel.  The C.felis component of the assay successfully 
detected the 13 samples that contained C.felis.  No false positives were detected in the 
known negative samples and no cross-reaction was observed. 
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3.4 Feline anaemia panel - Anaemia 1: FeLV, FIV and FCoV 
3.4.1 Initial single assay primer probe optimisation 
The FeLV, FIV and FCoV assays were optimised as single assays.  Each primer and probe 
was individually optimised and the optimal concentrations are given in Table 3.1. 
 
3.4.2 Multiplex primer probe optimisation 
The optimised assays were then multiplexed together and a 10-fold dilution series was 
used to assess the performance of the multiplex in comparison to the single assays.  At this 
stage any signs of crosstalk, cross-reaction and competition are investigated.  
 
From this initial assessment of sensitivity the FCoV component of the multiplex was found 
to be less sensitive in comparison to the single assay.  For FeLV the single assay detected 
the 10
-5 
dilution, whereas the multiplex assay detected to 10
-4
.  For FIV the single assay 
detected down to both the 10
-5
 and 10
-6
 dilutions in one out of two wells, the multiplex 
detected down to 10
-5 
in one out of two wells.  For FCoV the single assay detected the 10
-6
 
dilution in one out of two wells, the multiplex detected the 10
-4
 dilution (Table A-3).  
Therefore the sensitivity of the FCoV was greatly reduced in the multiplex in comparison 
to the single test.  In addition to the loss in endpoint detection limit for the assays, the trace 
quality was poor, with traces flattening out.  This experiment was repeated, and the 
multiplex endpoints were more comparable to the single tests (Table A-4), however 
flattening of traces was still evident.  Therefore a two-step RT-PCR kit designed for use 
with multiplex PCR assays was assessed; the Quanta qScript cDNA kit and Quanta 
multiplex qPCR supermix (Table A-5).  The endpoint detection limit and trace quality 
were not improved, in fact for FeLV in particular the multiplex endpoints were worse than 
previous results.  Overall the results suggested that the assay is not robust as a multiplex.   
 
A ‘plus/minus’ experiment was carried out to determine if one assay was responsible for 
the poor endpoint sensitivity and trace quality.  The results suggest that when FeLV is 
removed from the multiplex, the FIV traces improve, and FCoV traces slightly improve.  
FeLV did not improve whether FIV or FCoV were removed from the multiplex.  Attempts 
were made to optimise the FeLV assay within the multiplex by adapting probe 
concentration (assessing concentrations from 1.25µM to 20µM) and primer concentration 
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(assessing mixtures of concentrations of forward and reverse primers from 25µM to 
100µM), but these measures failed to improve the FeLV assay, or the FIV and FCoV 
assays within the multiplex.  Overall the results suggest that these assays do not work 
together as a triplex assay. 
 
3.5 Feline gingivitis multiplex 
3.5.1 Initial single assay primer probe optimisation 
The FeLV, FIV and FCV assays were optimised as single assays.  Each primer and probe 
was individually optimised using a strong positive control; the optimal concentrations are 
given in Table 3.1. 
 
3.5.2 Multiplex primer probe optimisation 
The optimised assays were then multiplexed together and a 10-fold dilution series was 
used to assess the performance of the multiplex in comparison to the single assays.  At this 
stage any signs of crosstalk, cross-reaction and competition were investigated. 
 
As with the anaemia 1 assay, issues with endpoint sensitivity were evident in this multiplex 
assay.  The FCV dilutions failed to amplify in the multiplex pool (Table A-6).  The 
experiment was repeated using a PCR kit specifically designed for use with multiplex 
assays, the Quanta qScript cDNA kit and Quanta multiplex qPCR supermix (Table A-7).  
The results suggested that there was a significant loss in sensitivity for the FeLV 
component of the multiplex in comparison to the single test.  In addition endpoint 
sensitivity of the FCV component of the multiplex was not improved, and trace quality was 
poor.  No further work was carried out on this assay in the timescale of the project. 
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3.6 Feline/canine gastroenteritis panel 
The GE panel consists of 3 multiplex screens; GE1: FPV/CPV, IC, GE2: FCoV, 
Salmonella, C.jejuni, and GE3: C.parvum, Giardia, T.foetus.  The optimisation and 
evaluation of these multiplex assays are described below.  
 
3.6.1 GE1: FPV/CPV and Internal control 
3.6.1.1 Initial single assay primer probe optimisation 
The parvovirus assay was optimised as a single assay.  Each primer and probe was 
individually optimised and the optimal concentrations are given in Table 3.1. 
 
3.6.1.2 Multiplex primer probe optimisation 
The optimised assays were then multiplexed together and a 10-fold dilution series was 
used to assess the performance of the multiplex in comparison to the single assays.  At this 
stage any signs of crosstalk, cross-reaction and competition are investigated.  
 
3.6.1.3 Crosstalk and cross-reaction 
No crosstalk or cross-reaction was observed in the multiplex.   
 
3.6.1.4 Competition 
As an IC is included in the assay, the possibility of competition was studied.  A dilution 
series of parvovirus was compared with and without IC in the sample (Table A-8) and the 
endpoint detection limit is similar with and without IC in the sample, and the IC had a 
consistent Ct value of ~28.  It is known that faecal samples positive for parvovirus can 
have a Ct of less than five, therefore strong positive samples will always out-compete the 
internal control.  However since this assay is qualitative and not quantitative, if a sample is 
found to be parvovirus positive and IC negative, then inhibition/competition is not 
significant.  
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3.6.1.5 Evaluation of the endpoint sensitivity of the multiplex in comparison 
to the single assays 
The endpoint detection limit of parvovirus in the duplex was compared to the single assay 
using a 10-fold dilution series of positive control.  The single assay detected the 10
-5
 
dilution in one out of two wells, whereas the duplex detected down to the 10
-5
 dilution in 
both wells (Table A-9).  These results suggest that there is no loss in sensitivity when the 
assay is multiplexed in comparison to the single assay. 
 
3.6.2 Intra-assay variability 
The robustness of the assay was determined by assessing the intra-assay variability of the 
assay.  The intra-assay variability (Table 3.4) of the parvovirus assay was found to be low 
(CoV 0.009).  The assessment of the inter-assay variability is ongoing.  
 
3.6.2.1 Evaluation of the clinical sensitivity and specificity of the multiplex 
The sensitivity and specificity of the duplex was evaluated using a panel of known positive 
and negative clinical samples. The duplex and single test successfully detected the 14 
parvovirus samples in the panel; in addition the assays detected another three parvovirus 
positive samples at higher Ct values (weak positive).  Contamination was not observed in 
either the negative controls extracted with the samples, or in the no-template controls; 
therefore these samples may be true positives and low level shedders.  There was no 
evidence of cross-reaction occurring in the duplex, and the single assay also detects the 
samples as positives.  Of the 17 samples negative for parvovirus by conventional gel based 
PCR (detection by gel electrophoresis), 14 were found negative by duplex and single PCR.  
A further 11 samples found to be negative by traditional PCR (total 28 negatives) were 
tested through the multiplex and were found to be negative.  The discrepant samples were 
retested by the GVDS and found to negative on repeat, this may suggest that the real-time 
PCR assay is more sensitive than traditional PCR, however this must be further 
investigated.  
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3.6.3 GE2: Coronavirus, Campylobacter jejuni and Salmonella 
3.6.3.1 Initial single assay primer probe optimisation 
The coronavirus, C.jejuni and Salmonella assays were optimised as single assays.  Each 
primer and probe was individually optimised and the optimal concentrations are given in 
Table 3.1. 
 
3.6.3.2 Multiplex primer probe optimisation 
The optimised assays were then multiplexed together and a 10-fold dilution series was 
used to assess the performance of the multiplex in comparison to the single assays.  At this 
stage any signs of crosstalk, cross-reaction and competition are investigated.  
 
3.6.3.3 Crosstalk and cross-reaction 
No crosstalk or cross-reaction was observed in the multiplex.   
 
3.6.3.4 Competition 
Mixed infections can occur in gastroenteritis cases therefore competition was assessed.  In 
total three panels of simulated samples were generated using eight dilutions manufactured 
from a strong positive control: one containing various concentrations of FCoV and 
Salmonella, one containing FCoV and C.jejuni and a third containing Salmonella and 
C.jejuni.  The dilution series from which these panels were manufactured were then tested 
using the singleplex assays.  The results are presented as a mean (unless they were 
positive/negative) in Tables A-10, A-11 and A-12.  Overall, the sensitivity of the FCoV 
assay is not affected when Salmonella or C.jejuni is present at any concentration.  The 
Salmonella and C.jejuni assays are both affected at the endpoint of detection in the 
presence of another strong pathogen.  However weak detection (Ct >35) of these pathogens 
may not be clinically significant.  If another pathogen is present at a higher level than it 
would be likely that this pathogen is causing illness, therefore the multiplex primer probe 
pool was not further optimised. 
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3.6.3.5 Evaluation of the endpoint sensitivity of the multiplex in comparison 
to the single assays 
The endpoint detection limit of each component of the multiplex was compared to the 
single assays using a 10-fold dilution series of a positive control tested in duplicate.  For 
FCoV both the multiplex and the single assay detected the 10
-3 
dilution.  For Salmonella 
the single and multiplex assays detected down to 10
-7
.  For C.jejuni the single assay 
detected the 10
-8
 dilution in one out of two wells, the multiplex detected the 10
-7
 dilution in 
one out of two wells (Table A-13).  Therefore there was no significant loss in sensitivity 
observed when the three assays were multiplexed. 
 
3.6.3.6 Intra-assay variability 
The robustness of the assay is determined by assessing the intra-assay variability of the 
assay.  The CoV values were low for each component; coronavirus CoV 0.005, C.jejuni 
CoV 0.005 and Salmonella CoV 0.004.  The intra-assay variability of the assay were found 
to be low (Table 3.4).  The inter-assay variability assessment is ongoing. 
 
3.6.4 GE3: Giardia, T.foetus and C.parvum 
3.6.4.1 Initial single assay primer probe optimisation 
The Giardia, T.foetus and C.parvum assays were optimised as single assays.  Each primer 
and probe was individually optimised and the optimal concentrations are given in Table 
3.1. 
 
3.6.4.2 Multiplex primer probe optimisation 
The optimised assays were then multiplexed together and a 10-fold dilution series was 
used to assess the performance of the multiplex in comparison to the single assays.  At this 
stage any signs of crosstalk, cross-reaction and competition are investigated.  
 
3.6.4.3 Crosstalk and cross-reaction 
No crosstalk or cross-reaction was observed in the multiplex.   
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3.6.4.4 Competition 
Mixed infections can occur in gastroenteritis cases therefore competition should be 
assessed.  It was not possible to assess competition in mixed infections as a strong enough 
T.foetus positive control could not be sourced in the timescale of the project. 
 
3.6.4.5 Evaluation of the endpoint sensitivity of the multiplex in comparison 
to the single assays 
The endpoint detection limit of each component of the multiplex was compared to the 
single assays using a 10-fold dilution series of a positive control tested in duplicate.  For 
Giardia both the multiplex and the single assay detected the 10
-4
.  For C.parvum the single 
assay detected down to 10
-4
 in one out of two wells, and the multiplex detected down to 10
-
3
.  For T.foetus the single assay detected the 10
-6
 dilution in one out of two wells, the 
multiplex detected the 10
-5
 dilution (Table A-14). 
 
A panel of clinical samples was not assessed for this multiplex in the timescale of the 
project. 
 
3.6.4.6 Intra-assay variability 
The robustness of the assay is determined by assessing the intra and inter-assay variability 
of the assay.  The CoV values were low for each component; T.foetus CoV 0.013, Giardia 
CoV 0.008 and C.parvum CoV 0.003 (Table 3.4).  The inter-assay variability assessment is 
ongoing. 
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CHAPTER 4  
4. Discussion 
The diagnosis of the causative agent in infectious disease in cats and dogs is essential to 
allow for the appropriate clinical intervention (Greiner and Gardener, 2000; Zarlenga and 
Higgins, 2001; Dahlhausen, 2010; Belak et al, 2013), reduce infection spread, and also for 
epidemiological and prevalence studies which in turn will better the understanding of the 
causes of infectious disease (Templeton et al, 2005; Gunson et al, 2008; Wolffs et al, 
2011).  In recent years PCR has replaced traditional detection methods as the gold standard 
diagnostic technique for many pathogens.  However replacing traditional detection 
methods with panels of internally controlled multiplex real-time PCR screens designed 
along syndromic lines is not widespread in veterinary laboratories.  This thesis describes 
the first phase of a project which aims to develop in-house multiplex assays for the 
detection of infectious diseases in cats and dogs.  It is hoped that in time the 
implementation of such assays may lead to significant service and clinical benefits as has 
been seen in human diagnostics, particularly for clinical virology (Gunson et al, 2008).  
 
After choosing the appropriate nucleic acid extraction platform, RT-PCR kit, real-time 
PCR platform, and internal control for the service, 17 real-time PCR assays were chosen 
with the aim of developing five syndrome based multiplex panels consisting of a total of 
nine multiplex assays (Table 1.1).  The multiplex assays were optimised and assessed for 
crosstalk, cross-reaction and competition, and then evaluated through a series of 
experiments to determine the endpoint sensitivity, specificity and robustness of each 
multiplex in comparison to the single assays, in some cases small panels of known positive 
and negative clinical samples were also assessed (Bustin et al, 2009).   
 
In the timescale of this project, the full optimisation and pre-clinical validation assessment 
of five multiplex assays were completed; feline respiratory screen, feline conjunctivitis 
screen and the feline/canine GE 1, 2 and 3 screens.  These multiplex assays were optimised 
to remove any issues of crosstalk and cross-reaction, and the multiplex assays performed 
well in comparison to the single assays when evaluated with dilution series and specificity 
panels.    The multiplex assays were found to be robust by assessment of the intra-assay 
variability, each multiplex had a low CoV value (less than 0.05), which suggests little 
variation was evident within a PCR run.  An IC was also successfully included in each 
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multiplex panel.  As described previously an IC is the ideal positive control and monitors 
for sample inhibition, PCR inhibition and PCR set-up error, therefore is essential for 
reliable and accurate diagnostics.  In this study the IC in each multiplex was not found to 
out-compete a positive target which would result in a false negative result, and the IC was 
not out-competed by a strong target which would result in a falsely inhibited result.  The 
possibility of competition was assessed for the feline conjunctivitis and the gastroenteritis 
2 screen and no significant competition was observed in these assays.  Competition in 
mixed infections is to be assessed for the feline respiratory multiplex and the GE 3 
multiplex.  Some of these multiplex assays were assessed with a limited panel of clinical 
samples and it should be noted that some issues arose with the feline respiratory screen and 
the GE 1 screen which is described in detail below.   
 
It should be noted that various issues arose during the optimisation and development of 
some of the multiplex assays, and although most of these issues were overcome by 
appropriate optimisation, laboratories intending to implement in-house multiplex real-time 
PCR should be aware of these potential issues and so plan and budget accordingly.  Firstly, 
access to strong positive control material to enable the optimisation of the primer probe 
pool was difficult at times.  This was a particular problem for pathogens that were not 
tested for at the GVDS (e.g. T.foetus), pathogens that had not previously been detectable 
by traditional methods (e.g. haemoplasmas), or pathogens of low prevalence.  
Collaboration with other centres worldwide allowed some positive control material to be 
sourced however these delays prevented the complete optimisation of some assays in this 
study (Anaemia 2 screen, GE 3 (T.foetus) and GE 4 screens).  For some assays plasmids 
were bought to allow the primers and probes of the single and multiplex assays to be 
optimised, however plasmids are expensive and so significantly increase the cost of 
optimising the assays.  In addition plasmid controls can increase the risk of test 
contamination resulting in false positive results therefore it is advisable to store stocks of 
plasmids in a different location to where testing is carried out.  It should be noted that the 
lack of available positive samples will have a significant impact on the ability to clinically 
validate these assays as access to positive material is essential. 
 
Veterinary molecular diagnostics is in its infancy and there are few relevant real-time 
assays published in the literature.  In some cases tests for particular pathogens were not 
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available which in turn resulted in some of the multiplex assays not being developed, for 
example in the proposed GE 4 screen a specific toxin real-time assay for C.difficile Toxin 
A could not be found.  A solution to this issue would be to design in-house assays, but with 
an additional lack of sequence data available to be able to design an assay, this was not 
possible.  Lack of published assays and sequence data will also affect future developments.  
For example a major issue with the ongoing expansion of the canine infectious disease 
panels is that no published real-time assay can be found for canine respiratory coronavirus 
or canine parainfluenza virus-1, and only one published assay for canine adenovirus-1 can 
be found.      
 
As described above many of the screens developed in this study were multiplexed with 
minimal optimisation, however some issues arose during optimisation.  Crosstalk was 
evident in both the feline respiratory and conjunctivitis multiplexes and although in both 
assays FAM was found to be crosstalking into the HEX channel, each multiplex had to be 
optimised differently to fully eliminate the crosstalk without resulting in a detrimental 
effect on any component in the multiplex.  This demonstrates that although the same probe 
dyes can be used in different multiplex assays, the optimisation required can be very 
different for each multiplex, highlighting again the experience and skill required to 
successfully optimise a multiplex assay. 
 
In addition to crosstalk, cross-reaction was observed in the feline respiratory screen.  
Cross-reaction such as in the case of the B.bronchiseptica can result in non-specific false 
positive traces, therefore it is essential that issues such as cross-reaction are assessed and 
overcome.  This was overcome by determining which components were cross-reacting and 
optimising these components.  To do this each primer and probe was removed from the 
respiratory multiplex and it was determined that cross-reaction did not occur when the 
B.bronchiseptica probe was removed.  Therefore it could be concluded that this probe was 
cross-reacting with not one but several components of the assay.  Reducing the 
B.bronchiseptica probe concentration eliminated the cross-reaction without having a 
detrimental effect on any component of the multiplex.  This again highlights the skill and 
experience needed to determine what is causing cross-reaction, and to optimise the 
multiplex assays to eliminate cross-reaction.  
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In some cases, assays were unable to be multiplexed at all.  An example of this was with 
the feline anaemia and gingivitis multiplex assays.  In both assays the FeLV assay could 
not be multiplexed with the other assays without significantly affecting sensitivity.  This 
highlighted that even with experience and careful optimisation there are occasions when 
assays simply will not be able to be multiplexed together.  Occasionally this can be 
overcome by using PCR kits specially designed for use with multiplex assays.  As 
mentioned in the introduction, RT-PCR kits specifically designed for multiplex assays 
which aim to reduce some of the issues caused by multiplexing such as crosstalk, cross-
reaction and competition are now available.  One such kit, the Quanta qScript cDNA 
kit/Quanta multiplex qPCR supermix kit was assessed with the FeLV containing 
multiplexes.  However as described in the results section the use of this kit did not improve 
the assay.  In the anaemia and gingivitis multiplexes components of the FeLV assay may 
have been inhibiting the other assays by cross-reacting with the other primers and/or 
probes.  Despite various attempts to optimise and reduce this effect, no improvement was 
seen.  Therefore as described previously, cross-reaction can cause false positives but can 
also cause false negatives by cross-reacting with other components in the multiplex and so 
inhibiting the assays.  One solution would be to use a single FeLV assay alongside a 
FIV/FCoV and FIV/FCV duplex assay, as the FIV, FCoV and FCV endpoint detection 
limits and trace quality improved when FeLV was removed from each multiplex.  However 
an alternative to removing FeLV from the multiplexes would be to source an alternative 
FeLV assay which may not cross-react with the other assays.  An alternative FeLV real-
time assay was sourced from the literature (Torres et al 2008); however it was not possible 
to assess this assay with the anaemia and gingivitis assays in the timescale of this project. 
 
Some of the optimised multiplex assays underwent limited further evaluation using small 
panels of positive and negative clinical samples.  Most performed as expected, detecting 
the appropriate samples as positive and failing produce false positives, however a notable 
exception was FCV.  Prior to the assessment of the respiratory multiplex with a panel of 
positive and negative respiratory clinical samples, the FCV component of the assay was 
found to be sensitive and specific for the target pathogens detecting all the expected 
controls.  However, on testing a further panel of FCV positive clinical samples the assay 
did not detect all the expected clinical samples.  This suggests that FCV PCR may be less 
sensitive than virus isolation.  In total three published real-time TaqMan FCV RT-PCR 
assays were assessed using a panel of known virus isolation FCV positive samples and 
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positive viral isolates.  Each FCV assay performed differently, failing to detect different 
samples and also detecting the same samples at variable Ct values.  The IC was positive 
and in the expected Ct range for all the samples indicating that no sample inhibition, PCR 
inhibition or PCR set-up error was causing this loss in sensitivity.  In an attempt to increase 
the performance of FCV PCR an in-house assay was then designed targeting the ORF1/2 
breakpoint region and was evaluated using the same panel of FCV isolates.  This region 
was chosen as a target as this region been successfully used as a target for norovirus 
assays.  The in-house designed assay was significantly less sensitive in comparison to the 
three published assays.  There was a lack of sequence data available to design the assay 
therefore a reason for the reduced sensitivity could be that there are in fact many more 
mismatches in this region than observed during development.   
 
It may be that FCV is so variable that a PCR has not yet been designed to sensitively detect 
all variants of the virus, and that the assays assessed here perform differently with different 
variants of the virus.  An interesting observation was that the Chander et al (2007) assay 
appeared to produce two distinct sets of amplification curves, one of the typed isolates 
FCV VI3 fitted in with the minority type of trace suggesting that these samples could be 
the same strain and that the assay does not amplify this strain as efficiently as others, 
sequencing of these samples would allow to further investigate these differences.  
Multiplexing the three published FCV assays together may improve overall FCV detection, 
however some virus isolation positive clinical samples were still undetected by any of the 
PCR assays.   
 
When looking at the Ct values of the clinical samples detected by the three published 
assays, the Ct values were high (weakly positive), and so it may be that the reduced 
sensitivity of PCR is clinically useful.  For example perhaps the PCR assay will only detect 
clinically significant infection i.e. cats shedding high levels of virus, whereas cats that are 
carriers shed low levels of virus, however further investigation is needed to determine the 
significance of the Ct value.  PCR usually improves sensitivity in comparison to traditional 
methods and so can detect DNA or RNA at low levels that may not be clinically 
significant.  However, in the case of FCV, the reduced sensitivity compared to virus 
isolation, may have some clinical value.         
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Ideally in order to assess and improve the FCV PCR a larger number of typed isolates and 
clinical samples, both virus isolation positive and negative, need to be assessed over a 
longer time period.  In addition the use of sequencing would be useful to further investigate 
discrepant samples and inform better test design.  The FCV component of the respiratory 
assay will remain in the multiplex however work will continue to improve the sensitivity of 
the FCV component. 
 
Another interesting outcome from the limited clinical sample evaluations related to the GE 
1 multiplex assay.  The GE 1 multiplex assay performed well when assessed with a small 
panel of positive and negative clinical samples detected by gold standard methods 
(traditional gel based PCR).  However an additional three positive samples were detected 
by the GE 1 screen.  These results could reflect an increase in sensitivity for the real-time 
PCR assay however these could also be false positive results.  These samples will require 
further analysis with alternative detection methods to determine if they are true parvovirus 
positives.  Real-time PCR can be more sensitive than traditional PCR, as stated above, care 
must be taken when comparing real-time PCR to other methods, even traditional PCR 
methods, as real-time PCR is often more sensitive (Mackay et al, 2002; Gunson et al, 
2008).  It is likely that the real-time PCR is more sensitive than traditional PCR at the 
endpoint of detection for parvovirus however this is yet to be proven.   
 
Overall this study demonstrates some of the pitfalls that may be encountered when 
developing an in-house multiplex real-time PCR diagnostic service.  Although it has been 
demonstrated that with careful optimisation most issues can be corrected, this process can 
incur costs and requires in depth experience of in-house multiplex real-time PCR.  It is 
important the laboratories considering implementing such assays realise that optimisation 
and test development issues are also frequently encountered post implementation once the 
assays are in routine use.  This process can also be costly and requires experience but is 
essential for a robust and quality service (Gunson et al, 2008).  Some examples of the 
expected ongoing issues are discussed below.  
 
When manufacturing new lots of multiplex PCR reagents (i.e. the multiplex primer and 
probe pools), the sensitivity and specificity of the newly developed reagents must be 
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compared to the current “in-use” reagents.  In order to do this, again the endpoint 
sensitivity (10-fold dilution panels of a positive control tested in duplicate) and the 
specificity (testing of no-template controls) of each new lot of reagents must be assessed 
and compared to the “in-use” lot to ensure that the new lot is as sensitive and specific as 
the previous lot.  If the new lot is found to be less sensitive or specific then the new primer 
probe pool will have to be re-optimised.  It is useful to manufacture primer probe pools in 
large lots as this reduces overall work load and limits the variation of the reagents over 
time.  This also applies to positive extraction controls and may also extend to different lots 
of PCR kit and extraction kit reagents. 
 
To ensure an assay is reliable and robust over time, the sensitivity and specificity must be 
monitored in each extraction and PCR run (Bustin et al, 2009).  In order to do this negative 
controls and positive controls for each target must be extracted alongside clinical samples 
and no-template controls should be tested on each PCR run.  The positive controls should 
be monitored over time to ensure any loss in sensitivity is detected.  If a loss in 
performance is evident, this assay can then be repeated, preventing the wrong results being 
reported.  If problems continue with the assay, then the assay must be troubleshooted to 
determine what component is failing, for example the primer probe pool, the positive 
control, the extraction, etc.  Negative extraction controls and no-template controls monitor 
for contamination in the system, in addition these controls may highlight other issues with 
reagents such as degradation of a primer probe pool which can also cause low level 
positive traces, which are false positive traces, and so could result in false positives being 
reported (Bustin et al, 2009).  Extensive record keeping of lot numbers of each reagent 
used in each real-time PCR run and the user carrying out the test is also useful as it can 
inform any troubleshooting of an assay.  For example, if a test performs badly i.e. the 
control is out of range, by looking back at record keeping it may be simple and easy to 
determine if a new primer probe pool lot had been used, or a new PCR kit lot etc.   
 
Awareness of the literature is also important as part of QC, novel types or variants of 
pathogens may evolve, therefore the sensitivity and specificity of the assays can change 
over time.  A good example in human diagnostics is influenza.  Influenza is a virus that 
evolves constantly (known as antigenic drift) with the emergence of new strains a common 
result.  In addition, influenza also re-assorts (known as antigenic shift) and so novel 
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influenza subtypes can emerge (Bennett et al, 2011).  Laboratories have to constantly 
ensure that tests are able to detect these newly emerging strains.  External QC panels are 
also useful for monitoring test performance; these panels contain a variety of relevant types 
and subtypes of a pathogen over a range of Ct values.  External QC panels are useful to 
help identify if the in-house assay is performing poorly, they also allow comparison of the 
in-house assay to methods used in different laboratories nationwide.   
 
For the reasons described some laboratories may not be keen to implement in-house 
molecular methods and so would wait for commercial solutions.  Currently there are no 
commercially available real-time multiplex PCR panels available for feline and canine 
infectious disease however these are likely to be available in the near future.  Commercial 
assays remove the need for extensive in-house quality control as the kit would contain a 
fully optimised assay with positive and negative control material and pre-determined 
quality control ranges (Bustin et al, 2009).  Reagents would therefore not be manufactured 
and assessed lot to lot in-house, and importantly a commercial company would be 
responsible for troubleshooting any issues with the multiplex primer probe pools, removing 
the need and cost of a highly experienced technician running the service.  However once a 
molecular service is implemented and the expertise is available an in-house service will be 
less costly, and future additions could be made to panels, and new panels developed with 
little extra cost. 
 
To summarise, this thesis describes the beginning phase of the development of a panel of 
in-house multiplex real-time PCR assays for the detection of feline and canine infectious 
disease.  Viruses are the major cause of infectious disease in cats and dogs although 
bacteria, parasites and fungi are commonly implicated.  Since these pathogens can present 
with indistinguishable clinical signs, it is essential to be able to determine the cause of 
infectious disease to enable appropriate clinical intervention, for example determining if 
the cause of disease is viral or bacterial changes the clinical intervention and disease 
management.  The real-time PCR assays described here will enable the simultaneous 
detection of DNA or RNA (RT-PCR), viruses, bacteria, parasites or fungi from a single 
sample.  These assays are envisaged to bring significant benefits to veterinary practices.   
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As found in human diagnostics traditional methods of detection can be insensitive and so 
many feline and canine pathogens may be under-diagnosed (e.g. rhinovirus in human 
infectious disease), real-time PCR can improve the overall detection and be particularly 
useful for fastidious pathogens (Templeton et al, 2005; Gunson et al, 2008; Wolffs et al, 
2011).  Therefore as well as associating more cases with an aetiological cause, a new 
understanding of clinical syndromes can develop as previously undiagnosed or under-
diagnosed pathogens may be more readily detected.  Furthermore the significance and 
clinical impact of mixed infections may become apparent; the use of sensitive multiplex 
real-time PCR assays at the WoSSVC highlighted that mixed infections were commonly 
detected in humans.  Using such sensitive assays in cats and dogs will enable the clinical 
importance of mixed infections to be investigated in these species. The use of multiplex 
PCR also standardises the detection method for the different pathogens in contrast to using 
several different detection methods to screen for a panel of pathogens, this in turn 
significantly reduces the turn around times from the receipt of a sample to the result being 
reported, which has significant clinical benefits.   
 
The use of sensitive detection techniques such as the real-time PCR multiplexes described 
here will be extremely valuable for use in epidemiological studies to determine more 
accurate figures on the actual prevalence of disease causing pathogens.  As described in the 
introduction, prevalence studies for most of the pathogens described in this study are 
published in the literature, however these studies have been carried out using various 
detection methods including traditional methods that may be insensitive, and so variable 
ranges of prevalence have been reported.  For example as detailed in the introduction the 
prevalence of B.bronchiseptica has been reported to range from as low as 0.4% to as much 
as 19% (Egberink et al, 2009) which is a vast range, making it difficult to truly determine 
the importance of this pathogen in feline respiratory disease.  The use of a sensitive 
detection method such as real-time PCR for epidemiology studies will provide more 
accurate prevalence data, in addition the use of multiplex real-time to detect several 
pathogens from one sample in one reaction will be advantageous as this generates more 
data rapidly for epidemiology studies.  These data can also inform public health where 
relevant, and if indeed the use of sensitive techniques such as real-time PCR results in 
certain pathogens being found to be more significant in causing disease than previously 
thought then this may potentially indicate the case for new vaccines to be developed for 
these pathogens, if not currently available.  In addition more sequencing data could result 
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in new variants being identified, and this new data could be used to improve current 
vaccines, making them more efficient in preventing disease.   
 
4.1 Future work 
Future work will include completing the full validation of the multiplex screens.  As 
mentioned above, not all aspects of the multiplex validation were completed in the 
timescale of the project.  Other aspects yet to be carried out as part of the multiplex 
evaluation include the assessment of the inter-assay variability of each assay.  The intra-
assay variability has been carried out and each assay was found to have good repeatability 
within a PCR run.  The inter-assay variability must be carried out to demonstrate the 
robustness of the assay over time, and so gives an indication of the reproducibility of the 
assay on different PCR runs, extraction runs and with different users.   
 
In addition the assessment of mixed respiratory infections has yet to be carried out to 
assess if any competition is evident between the targets.  Mixed infections are expected in 
respiratory samples, in fact data from the GVDS suggests approximately 25% of FCV 
positive samples will also be positive for FHV therefore the possibility of one positive 
target out-competing another weaker positive in a sample which would result in a false 
negative result must be evaluated.  One mixed FCV and FHV infection was tested by the 
respiratory multiplex and single assays and the FHV positive did out-competed the FCV 
positive resulting in a false negative FCV result by the multiplex, highlighting that 
competition may be an issue with this assay, and further optimisation or use of a multiplex 
RT-PCR kit may be necessary for this multiplex.  Mixed infections were not investigated 
in the timescale of this study as the FCV component of the multiplex was being further 
optimised and investigated. 
 
The anaemia and gingivitis assays will be multiplexed and assessed with an alternative 
FeLV assay, this will involve starting again from scratch to optimise the assay and so will 
increase the costs and time for the development of these screens, and if again the multiplex 
is unsuccessful, as stated above a single FeLV assay may be the only solution at this point 
in time, which would be more costly as samples would need to be tested by two assays. 
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Each assay must be clinically validated with a panel of relevant positive and negative 
clinical samples for each pathogen; this will be the last stage of evaluation and if the assays 
are comparable to the “gold standard” methods of detection then the assays can be 
implemented.  The molecular assays could be run alongside the current traditional methods 
for a time period to collect this data.  It is possible that problems will be encountered at this 
stage, as found with FCV, in which case the development of assays may have to go back to 
the drawing board and alternative assays assessed if available, which again would increase 
the time and costs for the development.  
 
While completing the validation of the five multiplex panels in this study, there are also 
ongoing plans are to develop other multiplex screens to this feline and canine infectious 
disease panel.  Work has begun on a canine respiratory screen which will screen for 
B.bronchiseptica, canine parainfluenza virus, canine adenovirus-2, canine herpesvirus, 
canine respiratory coronavirus, influenza A and Angiostrongylus vasorum.  Several other 
screens including a panel of ocular, neurological, hepatitis and abortion/fading pup screens 
for canines will be developed. As well as continuing to develop the assays described here, 
and extending the panels, the assays can be further developed to be able to quantify and 
even type as well as diagnose, this may be useful for FIV were the viral load may be 
clinically significant.   
 
Future collaborations with other research groups may provide the control materials and 
sequence data required to fully develop and improve the multiplex assays.  The GVDS 
plan to use Next Generation Sequencing (NGS) to further investigate and analyse clinical 
positive and negative samples, generating the sequence data required to continue the 
development of the molecular diagnostic service as well as bettering the understanding of 
the circulating pathogens causing feline and canine infectious disease.  In addition, further 
analysis of the clinical samples screened negative by the multiplex screens using NGS 
could result in novel pathogen discovery. 
 
As mentioned above commercial methods for the molecular detection of veterinary 
pathogens may become available in the near future.  Another future option may be to use 
point-of-care (POC) testing of cats and dogs where the veterinarian can rapidly screen the 
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animal in their practice, or indeed where tests can be used at home by the owner.  In 
humans, various POC assays are available at the bedside in wards, at local GP practices 
and at home.  Point of care assays do not require expertise staff to operate and therefore are 
easy to use and implement.  These POC assays provide rapid diagnosis that is sensitive and 
specific, and can be used for the detection antibody, antigen and molecular applications, 
and POC assays for antibody and antigen detections are currently available for cats and 
dogs.    In the future, it may be possible that the in-house PCR assays developed here will 
be adapted to POC assays.  Such testing methods would be of great advantage in shelters 
and boarding houses to enable the rapid screening of animals prior to entering, allowing 
infection control to be set up, preventing the rapid spread of infectious disease throughout 
the population of animals. 
 
4.2 Conclusions 
This thesis describes the initial phase of the development of an internally controlled 
syndrome based multiplex real-time PCR diagnostic service at the GVDS that will 
eventually replace traditional detection methods.  The results of this study highlight that 
the development of an in-house multiplex real-time PCR diagnostic service can be at times 
difficult and occasionally time-consuming.  Often these aspects are not discussed in the 
literature and as a result laboratories considering implementing/developing in-house 
multiplex assays may not be aware of these issues.  As this study has shown, most issues 
can be overcome by using the approaches described in this thesis but this requires 
experience of in-house multiplex techniques and can increase the costs of a development 
project.  However, despite this it is envisaged that in-house multiplex techniques will bring 
many advantages over current veterinary diagnostics; similar to what has been seen in 
human diagnostics - especially clinical virology. 
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Appendix 
Appendix 1 
Table A-1 Competition of each target with internal control in the conjunctivitis 
screen 
Dilution Feline herpesvirus Mycoplasma felis Chlamydophila felis 
No IC With IC No IC With IC No IC With IC 
10
-1
 18.76 19.74 N 19.29 20.11 30.06 17.75 18.66 33.65 
10
-2
 22.22 22.54 28.66 22.35 23.18 29.16 20.46 21.43 28.52 
10
-3
 25.86 25.90 28.78 25.68 26.02 29.01 24.03 24.71 28.50 
10
-4
 29.03 28.50 28.99 29.02 28.94 28.90 27.35 27.67 28.68 
10
-5
 32.05 30.80 29.02 32.18 31.61 29.14 31.00 30.82 29.04 
10
-6
 35.23 34.77 28.87 34.33 33.87 29.08 33.29 33.00 28.91 
10
-7
 36.58 36.26 29.20 38.96 N 29.14 36.04 36.06 29.15 
10
-8
 N N 29.47 N N NT N 38.23 28.98 
A 10-fold dilution series of each pathogen was assessed with and without an internal control in the sample to assess if there was any 
competition between the internal control and the target pathogens.  N: Negative; NT: Not tested; IC: internal control. IC Ct given in 
faded text under “with IC” column 
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Table A-2 Endpoint detection limit of the conjunctivitis multiplex in comparison to 
the single assay 
Dilution Feline herpesvirus Mycoplasma felis Chlamydophila felis 
Single Multiplex Single Multiplex Single Multiplex 
10
-1
 22.13 22.09 17.19 16.08 20.74 20.45 
10
-2
 24.77 24.63 20.07 19.27 24.08 23.92 
10
-3
 28.26 28.04 23.45 22.81 27.61 27.29 
10
-4
 31.48 31.34 26.63 25.75 30.83 30.78 
10
-5
 35.82 36.45 29.64 29.43 34.31 35.07 
10
-6
 37.11 38.10/N 33.00 32.16 37.7 28.19 
10
-7
 N N 35.08 35.04 N N 
10
-8
 N N 32.62 33.61 N N 
10
-9
 NT NT 31.45/N 36.88/N NT NT 
10
-10
 NT NT N N NT NT 
A 10-fold dilution series of each pathogen was assessed using a single assay for each pathogen and the multiplex assay.  N: negative; 
NT: not tested 
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Table A-3 Endpoint sensitivity of the anaemia 1 multiplex in comparison to the single 
assay 
Dilution Feline leukaemia 
virus 
Feline 
immunodeficiency 
virus 
Feline coronavirus 
Single Multiplex Single Multiplex Single Multiplex 
10
-1
 23.26 23.56 20.22 20.21 24.46 24.45 
10
-2
 26.36 26.42 23.60 23.98 28.07 28.04 
10
-3
 29.57 29.69 26.76 27.32 31.41 31.41 
10
-4
 33.08 39.69/N 30.17 30.41 34.57 N 
10
-5
 35.67 N 39.23/N 37.14/N 38.15 N 
10
-6
 N N 36.32/N N 38.29/N N 
10
-7
 N N N N N N 
10
-8
 N N N N N N 
A 10-fold dilution series of each pathogen was assessed using a single assay for each pathogen and the multiplex assay.  N: Negative 
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Table A-4 Repeat testing of the endpoint sensitivity of the anaemia 1 multiplex in 
comparison to the single assay 
Dilution Feline leukaemia 
virus 
Feline 
immunodeficiency 
virus 
Feline coronavirus 
Single Multiplex Single Multiplex Single Multiplex 
10
-1
 26.83 26.26 26.59 27.18 25.31 25.49 
10
-2
 30.05 29.97 29.50 30.92 28.64 28.74 
10
-3
 32.39 36.68 37.06/N 33.62 31.54 31.56 
10
-4
 N N N N 37.15 38.40/N 
10
-5
 N N N N N N 
10
-6
 N N N N N N 
10
-7
 N N N N N N 
10
-8
 N N N N N N 
A 10-fold dilution series of each pathogen was assessed using a single assay for each pathogen and the multiplex assay.  N: negative  
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Table A-5  Endpoint detection limit of the anaemia 1 multiplex in comparison to the 
single assay using the Quanta RT-PCR mastermix kit 
Dilution Feline leukaemia 
virus 
Feline 
immunodeficiency 
virus 
Feline coronavirus 
Single Multiplex Single Multiplex Single Multiplex 
10
-1
 25.96 28.17 25.48 28.06 24.17 26.37 
10
-2
 29.39 31.67 29.11 30.27 27.38 30.10 
10
-3
 31.84 N 37.23 35.50/N 30.14 32.87 
10
-4
 35.17 N 38.46/N N 32.85 35.80/N 
10
-5
 37.20/N N N N 35.22 N 
10
-6
 N N N N 37.17 N 
10
-7
 N N N N 34.98 N 
10
-8
 N N N N N N 
A 10-fold dilution series of each pathogen was assessed using a single assay for each pathogen and the multiplex assay using a PCR kit 
designed for use with multiplex PCR.  N: negative 
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Table A-6 Endpoint detection limit of the gingivitis multiplex in comparison to the 
single assay 
Dilution Feline leukaemia 
virus 
Feline 
immunodeficiency 
virus 
Feline coronavirus 
Single Multiplex Single Single Multiplex Single 
10
-1
 16.16 16.38 23.86 24.25 30.58 N 
10
-2
 19.15 19.35 27.11 27.00 33.96 N 
10
-3
 22.32 22.55 29.51 30.20 37.77 N 
10
-4
 25.56 25.84 32.56 34.35 38.37/N N 
10
-5
 28.85 28.28 N 35.16/N N N 
10
-6
 31.96 34.72 N N N N 
A 10-fold dilution series of each pathogen was assessed using a single assay for each pathogen and the multiplex assay.  N: negative 
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Table A-7 Repeat of the endpoint detection limit of the gingivitis multiplex in 
comparison to the single assay 
Dilution Feline leukaemia 
virus 
Feline 
immunodeficiency 
virus 
Feline coronavirus 
Single Multiplex Single Single Multiplex Single 
10
-1
 28.26 27.36 24.22 24.07 25.96 24.86 
10
-2
 32.29 N 27.30 27.13 29.39 N 
10
-3
 35.31 N 30.79 30.58 32.7 N 
10
-4
 N N N N 38.58 N 
10
-5
 N N N N N N 
10
-6
 N N N N N N 
10
-7
 N N N N N N 
10
-8
 N N N N N N 
A 10-fold dilution series of each pathogen was assessed using a single assay for each pathogen and the multiplex assay.  N: negative 
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Table A-8 Competition of each target with internal control in the gastroenteritis 1 
screen 
Dilution Parvovirus (PV) 
No IC With IC 
PV IC 
10
-1
 21.15 20.43 28.22 
10
-2
 24.24 23.71 28.26 
10
-3
 27.41 26.45 28.43 
10
-4
 30.87 29.79 28.34 
10
-5
 N N 28.32 
10
-6
 N N 28.21 
10
-7
 N N 28.32 
10
-8
 N N 28.45 
A 10-fold dilution series of parvovirus was assessed with and without an internal control in the sample to assess if there was any 
competition between the internal control and the target pathogen.  N: negative; IC: internal control 
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Table A-9 Endpoint detection limit of the gastroenteritis 1 (parvovirus and internal 
control) screen in comparison to the single assay 
Dilution Single Multiplex 
10
-1
 17.62 17.35 
10
-2
 21.42 21.54 
10
-3
 23.61 23.88 
10
-4
 31.82 27.95 
10
-5
 37.82/N 34.63 
10
-6
 N N 
10
-7
 N N 
10
-8
 N N 
A 10-fold dilution series of parvovirus was assessed using a single assay and the multiplex assay.  N: negative; NT: not  tested. 
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Table A-10 Competition between targets in the gastroenteritis 2 screen: coronavirus 
against Salmonella 
 
Salm -1 
24.09
a
 
Salm -2 
27.22 
Salm -3 
30.67 
Salm -4 
33.58 
Salm -5 
34.92 
Salm -6 
N 
Salm -7 
N 
Salm -8 
N 
corona -1 
24.07
b
  
24.83 
24.86 
28.02 
25.18 
31.16 
24.98 
34.89 
25.05 
N 
25.25 
N 
25.12 
N 
25.10 
N 
25.25 
corona -2 
27.31  
24.84 
28.33 
28.32 
28.03 
31.68 
28.64 
36.05 
28.18 
N 
28.21 
N 
28.30 
N 
28.71 
N 
28.39 
corona -3 
30.21 
24.94 
32.05 
28.45 
32.01 
31.61 
31.71 
36.01 
31.39 
N 
32.10 
N 
31.56 
N 
31.26 
N 
31.25 
corona -4 
34.24  
24.98 
34.18 
28.64 
N 
32.32 
34.12 
36.74 
34.49 
N 
34.03 
N 
35.23 
N 
N 
N 
34.24 
corona -5 
N 
24.76 
N 
28.19 
N 
31.97 
N 
36.21 
35.13 
N 
35.20 
N 
N 
N 
N 
N 
N 
corona -6 
35.38 
24.67 
N 
28.56 
N 
31.57 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
corona -7 
N  
24.76 
N 
28.35 
N 
31.33 
N 
34.55 
N 
N 
N 
N 
N 
N 
N 
N 
N 
corona -8 
N  
24.97 
N 
28.51 
N 
31.24 
N 
33.95 
N 
N 
N 
N 
N 
N 
N 
N 
N 
Panels of simulated samples were generated using eight dilutions manufactured from a strong positive control and tested to assess if any 
competition existed between targets in a multiplex.  Salmonella Ct values are in blue
a
, and coronavirus Ct values are in green
b
.  N: 
negative; salm: salmomella; corona: coronavirus 
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Table A-11 Competition between targets in the gastroenteritis 2 screen: coronavirus 
against Campylobacter jejuni 
 
C.jejuni  
-1 
25.98
a
 
C.jejuni 
-2 
28.81 
C.jejuni 
-3 
32.64 
C.jejuni 
-4 
37.77 
C.jejuni 
-5 
N 
C.jejuni 
-6 
N 
C.jejuni 
-7 
N 
C.jejuni 
-8 
N 
corona-1 
24.29
b 
 
26.70 
25.46 
30.41 
25.61 
33.20 
26.00 
N 
25.61 
N 
25.31 
N 
25.69 
N 
25.57 
N 
25.56 
corona-2 
28.06  
26.35 
28.99 
30.17 
28.75 
34.18 
29.06 
34.35 
29.01 
N 
29.23 
N 
N 
N 
29.09 
N 
29.20 
corona-3 
30.98 
26.58 
31.80 
29.60 
32.34 
33.71 
32.32 
35.47 
32.07 
N 
N 
N 
31.84 
N 
32.27 
N 
31.90 
corona-4 
34.28  
27.02 
34.11 
30.06 
34.73 
34.16 
35.12 
36.71 
N 
37.31 
35.75 
N 
34.16 
37.80 
35.65 
N 
36.03 
corona-5 
N 
26.48 
N 
29.90 
N 
34.38 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
corona -6 
N 
26.31 
N 
29.86 
N 
33.41 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
corona -7 
N  
26.71 
N 
29.57 
N 
33.85 
N 
36.63 
N 
N 
N 
N 
N 
N 
N 
N 
N 
corona -8 
N  
26.39 
N 
30.08 
N 
33.12 
N 
37.15 
N 
N 
N 
N 
N 
N 
N 
N 
N 
Panels of simulated samples were generated using eight dilutions manufactured from a strong positive control and tested to assess if any 
competition existed between targets in a multiplex. Campylobacter jejuni Ct values are in blue
a
, and coronavirus Ct values are in green
b
  
N: negative; corona: coronavirus; C.jejuni: Campylobacter jejuni 
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Table A-12 Competition between targets in the Gastroenteritis 2 screen: 
Campylobacter jejuni against Salmonella 
 
C. jejuni 
-1 
25.39
a
 
C. jejuni 
-2 
29.47 
C. jejuni 
-3 
32.34 
C. jejuni 
-4 
34.66 
C. jejuni 
-5 
37.07 
C. jejuni 
-6 
N 
C. jejuni 
-7 
N 
C. jejuni 
-8 
N 
Salm -1 
24.01
b
  
26.61 
24.88 
30.12 
24.96 
33.24 
25.00 
36.67 
24.77 
N 
24.93 
N 
25.22 
N 
25.14 
N 
25.02 
Salm -2 
27.43 
26.96 
28.32 
30.11 
28.65 
33.16 
28.64 
N 
28.70 
N 
28.80 
N 
28.44 
N 
28.46 
N 
28.51 
Salm -3 
30.93 
27.12 
32.42 
30.33 
32.17 
32.92 
32.05 
N 
N 
N 
32.09 
N 
32.38 
N 
31.75 
N 
32.72 
Salm -4 
34.18 
26.95 
N 
30.32 
N 
32.84 
36.03 
36.16 
36.02 
N 
N 
N 
34.37 
N 
36.51 
N 
34.11 
Salm -5 
N 
27.09 
N 
30.18 
N 
33.98 
N 
36.32 
N 
N 
N 
N 
N 
N 
N 
N 
N 
Salm -6 
N 
27.22 
N 
30.47 
N 
33.65 
N 
36.42 
N 
N 
N 
N 
N 
N 
N 
N 
N 
Salm -7 
N  
27.24 
N 
30.75 
N 
34.04 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
Salm -8 
N  
27.08 
N 
30.28 
N 
33.51 
N 
37.70 
N 
N 
N 
N 
N 
N 
N 
N 
N 
Panels of simulated samples were generated using eight dilutions manufactured from a strong positive control and tested to assess if any 
competition existed between targets in a multiplex.  Campylobacter jejuni Ct values are in blue
a
, and Salmonella  Ct values are in 
green
b
  N: negative; Salm: Salmonella; C.jejuni: Campylobacter jejuni 
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Table A-13 Endpoint detection limit of the gastroenteritis 2 multiplex in comparison 
to the single assays 
Dilution Coronavirus Salmonella Campylobacter jejuni 
Single Multiplex Single Multiplex Single Multiplex 
Neat 25.99 26.47 21.01 21.07 13.75 13.73 
10
-1
 29.21 29.51 24.39 24.28 16.03 16.39 
10
-2
 37.71 32.63 27.75 27.77 19.21 19.39 
10
-3
 34.92 35.78 31.42 31.45 23.16 22.23 
10
-4
 N N 35.05 34.81 26.28 26.38 
10
-5
 N N N N 30.40 29.08 
10
-6
 N N N N 33.76 32.03 
10
-7
 NT NT NT NT 35.16 34.56/N 
10
-8
 NT NT NT NT 37.29/N N 
10
-9
 NT NT NT NT N N 
10
-10
 NT NT NT NT N N 
A 10-fold dilution series of each pathogen was assessed using a single assay for each pathogen and the multiplex assay.  N: negative; 
NT: not tested 
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Table A-14 Endpoint detection limit of the gastroenteritis 3 screen in comparison to 
the single assays 
Dilution Cryptosporidium 
parvum 
Giardia Tritrichomonas 
foetus 
Single Multiplex Single Multiplex Single Multiplex 
10
-1
 22.26 22.24 23.04 24.00 26.64 26.44 
10
-2
 26.99 26.93 25.85 27.59 28.29 27.23 
10
-3
 30.98 30.87 29.26 30.85 31.11 28.83 
10
-4
 35.62/N N 33.33 37.94 33.36 30.89 
10
-5
 N N N N 37.08 35.66 
10
-6
 N N N N 38.74/N N 
10
-7
 N N N N N N 
10
-8
 N N N N N N 
A 10-fold dilution series of each pathogen was assessed using a single assay for each pathogen and the multiplex assay.  N: negative;  
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